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Abstract 
Background. Peroxiredoxin 2 (Prx2) is a typical 2-cysteine (Cys) peroxiredoxin 
ubiquitously expressed. Prx2 is able to efficiently scavenge H2O2 and other hydro-peroxides 
to maintain intracellular redox balance. Prx2 has been largely studied in red cells, where it 
acts as antioxidant system and chaperone-like molecule. Although growing evidences 
indicate the important role of Prx2 in different cell models, much still remains to be 
investigated in complex disease scenario such as chronic lung disease or stress erythropoiesis.  
 
Aim. The major aim of my work is to understand the functional role of Peroxiredoxin 
2 in a mouse model of pulmonary artery hypertension. 
 
Section 1. I focus on the functional role of peroxiredoxin-2 (Prx2) in lung 
homeostasis. Here, I studied the events related to the generation of pulmonary artery 
hypertension (PAH), a life threatening and highly invalidating chronic disorder. Hypoxia was 
used as trigger factor. I found that Prx2-/- mice displayed chronic lung inflammatory disease 
associated with (i) abnormal pulmonary vascular dysfunction; and (ii) increased markers of 
extracellular-matrix remodelling.  Rescue experiments with in vivo the administration of 
fused-recombinant-PEP-Prx2 to hypoxic mice show a reduction in pulmonary inflammatory 
vasculopathy and down-regulation of autophagy. Thus, we propose Prx2 plays a pivotal role 
in the early stage of PAH as multimodal anti-oxidant system targeting oxidation, 
inflammatory vasculopathy and indirectly autophagy. 
Section 2. I have studied the effect of iron-overload (IO) diet on Prx2-/- mouse 
erythropoiesis and its link with iron homeostasis. In Prx2-/- mice, IO displayed a potent 
cytotoxic effect on erythropoiesis and it was associated with lacking in liver STAT3 
activation. This results in low hepcidin expression. Treatment with PEP Prx2 ameliorates IO-
induced anemia and restored liver STAT3 activation, with adequate hepcidin expression in 
relation to IO. The importance of Prx2 on the axis between erythropoiesis and iron 
metabolism is also supported by the beneficial effects of PEP Prx2 on hepcidin levels a 
mouse model of β-thalassemia. 
Section 3. I have studied a humanized mouse model for sickle cell disease (SCD, 
Tim Townes mouse model). Based on the revision of the literature, SCD and healthy mice 
were supplemented with ω-3 fatty acids. Hypoxia/reoxygenation stress was used to mimic 
SCD acute vaso-occlusive crisis. We found that ω-3 fatty supplementation reduces: (i) sickle 
cell related oxidative stress, (ii) systemic and local (lung and liver) inflammatory response, 
(iii) vascular endothelial activation and (iv) vascular dysfunction. Our data generate a 
rationale for ω-3 fatty supplementation in clinical management of SCD patients.  
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PEP Prx2: Prx2 fused to cell penetrating carrier PEP1 peptide 
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Introduction 
 
 
Peroxiredoxin-2 (Prx2) plays a pivotal role as anti-oxidant system in cell 
homeostasis 
Peroxiredoxin 2 (Prx2) is a typical two-cysteine peroxiredoxin and is ubiquitously 
expressed (1). Prx2 is able to reduce and detoxify H2O2 and other hydroperoxides 
based on its redox-active cysteine residue present in the catalytic site (Fig. 1). The 
second conserved cysteine, known as the resolving cysteine, reacts with the sulfenic 
acid to form a disulphide bridge, which is rapidly reduced by Thioredoxin (Trdx) (2, 
3). Although peroxiredoxins have been involved in cellular defense mechanism 
against oxidative stress, recent reports suggest a possible role of peroxiredoxin(s) as 
molecular chaperone in cell proteostasis (4). 
 
 
 
 
Fig. 1 Molecular surface analysis of the five-dimeric 
thoroid structure of Peroxiredoxin-2 (Prx2) (modified 
from Matté A et al. FRBM 2013 (5)). Regions negatively 
charged are represented in red. In blue positively charged 
regions are shown. The white areas represent regions 
without charge.  
 
Prx2 is the third protein for abundance in red blood cells (RBCs), which have 
been used as cell model for Prx2 characterization. In vitro studies have shown that 
Prx2 is one of the key RBC antioxidant systems, facing low endogenous levels of 
H2O2 (2, 6). Although progresses have been made on the knowledge of Prx2, much 
still remains to be investigated on its function in response to stress during red cell 
senescence and in pathological erythropoiesis.  
The generation of a mouse genetically lacking Prx2 (Prx2-/-) offers the possibility 
to functionally characterize Prx2. Prx2-/- mice display a mild hemolytic anemia with 
ineffective erythropoiesis and splenomegaly. An in vitro study has shown that Prx2-/- 
mouse red cells display a lower sensitivity to exogenous H2O2 or organic peroxides 
compared to RBCs lacking other antioxidant systems such as catalase or glutathione 
peroxidase 1 (Gpx1) (7). This finding suggests additional role for Prx2 in RBCs 
beside its anti-oxidant function. Indeed, Prx2 is also important in maintaining RBCs 
membrane features (5, 8). Recently, we have shown that Prx2 translocates to the RBC 
membrane in response to exogenous oxidative stresses (e.g. diamide) or hypoxia (9). 
Band 3 is the membrane-docking site for Prx2, which plays an important role as local 
cytoprotector of Band 3, the main RBC membrane integral protein (5). It is of note 
that hemichromes also bind to Band 3 and compete with Prx2 on Band 3 N-terminal 
cytoplasmic domain (10). Studies on RBCs have shown that membrane oxidation 
promotes Band 3 aggregation, which is linked to increase Band 3 tyrosine 
phosphorylation, mediated by Syk kinase activation (11-13). In Prx2−/− mouse 
erythrocytes, we found increased membrane oxidative damage and reduced RBC 
survival, which is associated with increased RBCs phagocytosis. Membrane 
translocation of heat shock proteins HSP70 and 27 is not enough to counteract the 
severe membrane oxidative damage of RBC lacking Prx2 (Fig. 2). The combination 
of severe oxidative stress and activation of Syk-mediate signaling results in increased 
vesciculation of Prx2−/− mouse RBCs to clear damage proteins and oxidized 
hemoglobin (Fig. 2) (8). 
 
 
 
 
Fig. 2. Schematic diagram of the role of Prx2 in redox response to maintain red cell membrane proteostasis  
(modified from Matté A. et al. FRBM 2014 (8)). In wild-type mice, the oxidative stress induces translocation to 
the membrane of HSPs and Prx2, which limits membrane protein damage and the activation of Syk kinase, which 
phosphorylates Band 3. In Prx2-/- mice, the absence of Prx2 promotes membrane oxidative damage and 
translocation to the membrane of a high amount of HSPs, which are unable to counteract Band 3 oxidation and 
clusterization, favored by the high activation of Syk. This results in fast removal of prematurely damaged Prx2 -/- 
RBCs by the macrophage system and increases the release of erythroid MPs that clear damaged proteins and 
oxidized hemoglobin. Prx2: peroxiredoxin 2; red blood cells (RBC); B3: Band 3; Syk: Src related Tyrosine 
Kinase; P: phosphorylation of Tyrosine residues on band 3; HMCs: hemichromes; HSPs: heat shock proteins; 
MPs: microparticles; NAC: N-Acetyl-Cysteine.  
 
Li J. et al. have recently shown that Prx2 is highly expressed during normal 
human and mouse erythropoiesis, suggesting an important role of Prx2 during 
erythroid maturation (14). Indeed, mice genetically lacking Prx2 show ineffective 
erythropoiesis associated with extramedullary erythropoiesis similar to that observed 
in β-thalassemic mice (15). Increased ROS levels and apoptosis characterize Prx2-/- 
mouse erythropoiesis. This is associated with the activation of Nrf2, a redox-sensitive 
transcriptional factor, resulting in increased expression of ARE-related genes for anti-
oxidant systems (15). To explore the role of Prx2 during stress erythropoiesis, we 
have backcrossed β-thalassemic mice (Hbbth3/+) with Prx2-/- mice. We have observed 
that the absence of Prx2 worsens β-thalassemic ineffective erythropoiesis with 
increased ROS level and cell apoptosis compared to β-thalassemic mice. In Prx2-/-
Hbbth3/+, Nrf2 is activated as back-up mechanism against severe oxidation related to 
the absence of Prx2. The functional interplay between Prx2 and Nrf2 is further 
supported by rescue experiments, using the fused recombinant protein PEP1-Prx2. 
Hbbth3/+ and Prx2-/-Hbbth3/+ mice treated with PEP1-Prx2 show an amelioration of 
both hematologic phenotype and ineffective erythropoiesis. In addition, PEP1-Prx2 
treated Hbbth3/+ mice also display a significant reduction in liver iron-overload, 
supporting the key role of Prx2 in limiting β-thalassemic related organ damage (15). 
Collectively, these data highlight a new adaptive mechanism against oxidative stress 
involving Nrf2-Prx2 interplay in stress erythropoiesis. Our data also suggest the 
modulation of endogenous antioxidant systems as a new possible therapeutic option 
in pathologic erythropoiesis. 
Fig. 3. Schematic diagram on the interplay between peroxiredoxin-2 (Prx2) and Nrf2 cooperating to limit 
oxidative damage in β-thalassemic erythropoiesis (modified from Matté A. et al. ARS 2015 (15)). In WT mice, 
the physiological generation of ROS during erythropoiesis is controlled by antioxidant systems such as Prx2 and 
Nrf2 is inactive. The acute oxidative stress induced by PHZ activates Nrf2, which upregulates ARE-genes of 
antioxidant systems (e.g. Hmox1, Gstm, or Nqo1). The absence of Prx2 promotes ineffective erythropoiesis and 
increases ROS levels with associated activation of Nrf2 as a backup mechanism to control oxidative stress. In β-
thalassemic erythroid precursors, despite the upregulation of Prx2, oxidative stress promotes t he activation of 
Nrf2. PEP1-Prx2 treatment ameliorates ineffective erythropoiesis and reduced ROS levels. In Prx2-/-Hbbth3/+mice, 
the absence of Prx2 worsens β-thalassemic hematological phenotype and ineffective erythropoiesis with a further 
increase in ROS levels and further activation of Nrf2. PHZ: phenylhydrazine; ROS: reactive oxygen species; 
ARE: antioxidant responsive element; Hmox1: heme oxygenase 1; Gstm: Glutathione S-transferase Mu 1; Nqo1: 
NAD(P)H-quinone oxidoreductase 1. 
 
We carried out a revision of the literature and we found that the contribution of 
Prx2 to cell homeostasis is not to be limited to erythroid cells. In fact, a study on 
Prx2-/- mice has shown an higher sensitivity of these animals to LPS-induced 
endotoxic shock, possibly related to perturbation of innate inflammatory response 
(16). Platelets seem also to be affected by the absence of Prx2, which has been 
proposed to act as protective antioxidant enzyme against collagen-stimulated platelet 
activation and platelet-dependent thrombosis (17). 
Peroxiredoxin-2 (Prx2) is protective against oxidative related organ damage 
Since Prx2 is ubiquitously expressed, studies have been carried out to characterize 
Prx2 in different disease models, characterized by oxidative stress and inflammation, 
such as cardiovascular diseases, brain ischemia or acute lung injury (Table 1).  
Prx2 and cardiovascular system (Table 1). Apo-E-/- mice, a known model for 
atherosclerosis, show accelerated arterial plaque formation in absence of Prx2 
associated with an early development of atherosclerosis compared to wild-type mice 
(18). This has been related to enhanced activation of redox-depending signaling 
systems, involving p38 mitogen-activated protein kinase, that participates to 
endothelial vascular activation (e.g.: increased expression of Vascular cell adhesion 
molecule 1 (vCAM-1), Intercellular adhesion molecule 1 (ICAM-1) and Monocyte 
chemoattractant protein-1 (MCP-1) (18). The overexpression of Prx2 protects 
cardiomyocyte from oxidative stress (19, 20). 
Prx2 and brain (Table 1). Ischemia followed by re-oxygenation is a strong pro-
oxidant stimulus. In mouse model for post-ischemic brain injury, peroxiredoxins 
(Prx2 and 5) have been proposed to act as anti-oxidant system but also as DAMPs 
(damage-associated molecular pattern molecules), inducing IL-23 expression via 
TLR2 and TLR4. This modulates macrophages infiltration, regulating the local 
inflammatory response (21). Overexpression of Prx2 has been shown again to be 
protective against ischemic/reperfusion damage. The cytoprotective role of Prx2 has 
been also proposed to play a role in the response to either ischemic or age-linked 
neuronal cell damages in  different brain areas (22-24). 
Prx2 and lung (Table 1). Studies in Prx2-/- mice have highlighted the protective 
role of Prx2 against ovalbumin-induced mouse asthma, through the reduction of ROS 
(25). There are some evidences that Prx2 co-localizes with PDGFR and with markers 
of proliferating cells in the epithelium and lung parenchyma of patients with 
idiopathic pulmonary fibrosis (IPF) (26). In in vitro-cell based assay, epithelial cells 
overexpressing Prx2 are more resistant against formaldehyde-induced cell apoptosis 
(27).  
Prx2 and skin (Table1).  The absence of Prx2 has been shown to promote an 
accelerated cell aging in Prx2-/- mouse embryonic fibroblasts (MEFs). This involves 
(i) increased intracellular ROS production; (ii) cell cycle arrest in G2/M phase; and 
(iii) activation of p38 and ERK signaling pathway. In vivo, mice lacking Prx2 show 
accelerated skin aging and decreased dermis collagen mediated by the activation of 
ERK-JNK axis (28).  
Table 1. Role of Peroxiredoxin-2 in different cell systems and disease models 
 
 
Key results Refs  
In vitro 
Vascular cells 
 In vascular endothelial cells (VECs), Prx2 acts as  antioxidant regulator of VEGF-VEGFR2 signalling pathway. 
Prx2 protects VEGFR2 by blocking H2O2-dependent oxidation. 
 Cardiomyocytes overexpressing Prx2 are more resistant to H2O2-induced cell death and apoptosis . This has been 
related to increase expression of  Bcl-2, and decrease expression of Bax and of active caspases 3, 9 and 12. 
(29) 
(19) 
Immune-related cells 
 CD8+ T cells genetically lacking Prx2 display increase ROS levels and decrease survival. 
 In BMDMs (bone marrow-derived macrophages), the anti-oxidant activity of Prx2 prevents the LPS-induced 
inflammatory gene expression and the activation of NF-kB, probably through the modulation of NADPH oxidase 
function.  
 Under inflammation, Prx2 is released from macrophages and it may act as cellular damage signal. Human 
recombinant Prx2 is able to induce macrophages release of TNF-α in absence of other stimuli. 
(30) 
(16) 
(31) 
Neuronal cells 
 In neuronal differentiated MN9D DA cells, Prx2 protects against 6-OHDA neurotoxicity inhibiting ASK1 and 
JNK/p38 pro-death signalling pathway. 
 In neuronal cells, S-nitrosylation of endogenous Prx2 reduces its anti-oxidant power against oxidative stress, 
promoting neuronal cell death. 
 In cortical neuronal cells, overexpression of Prx2 is protective against oxidation (e.g.: cumene hydroperoxide) 
and in vitro ischemia (oxygen-glucose deprivation).  
 During neurogenesis, Prx2 protects  ESC (embryonic stem cells) stemness against ROS injury. 
(32) 
(33) 
(34) 
(35) 
HeLa cells 
 In hypoxic human HeLa cells, Prx2 and Prx4 interact with HIF-1α and HIF-2α. Prx2 is a direct HIF target gene 
and its expression is induced by prolonged hypoxia. 
(36) 
Lung epithelial cell 
line 
 In lung epithelial cells treated with formaldehyde, the overexpression of Prx2 protects against cell apoptosis, 
through increased Bax activation and decreased Bcl-2, Caspase 3 and Caspase 9 function. 
(37) 
In vivo 
RBCs and 
erythropoiesis 
 Prx2 is the third most abundant protein in RBCs and shows both cytosolic and membrane localization. It plays 
major roles against oxidative stress, preventing RBCs senescence. It scavenges low levels of hydrogen peroxide, 
maintains hemoglobin stability and prevents membrane oxidative damage. It is important in different red cell 
pathologies such as spherocytosis, sickle cell disease, β-thalassemia and chorea-acanthocytosis. 
 Prx2-/- mice display a mild hemolytic anaemia. 
 The absence of Prx2 promotes ineffective erythropoiesis similar to β-thalassemia. Prx2 plays an important role in 
preventing ROS mediated DNA damage inducing apoptosis and cell cycle arrest by p53 signalling pathway 
activation. Prx2
-/-
 mice show activation of Nrf2 in orthochromatic erythroblasts, acting as back-up mechanism 
against severe oxidative stress. 
(2) (3) 
(9) (38)   
(15) (8) 
(39) 
(40) (7) 
(41) 
(42)  
(43) 
(44) 
Brain 
 In hippocampus, Prx2 plays a role in age-associated physiological functions . It is required to preserve synaptic 
plasticity.  
 Prx2-/- mice show cognitive defects, linking Prx2 to age-dependent mitochondrial oxidative damage. Dietary 
vitamin E alleviated Prx2
-/- 
neurologic phenotype. 
 Prx2 protects mice against ischemic/reperfusion brain injury through scavenging ROS, attenuating DNA damage 
and inhibiting different pro-death cascades (ASK1/JNK-, PARP1- and p53- dependent death pathways). 
 Mice overexpressing Prx2 are protected against 6-OHDA-induced degeneration (Parkinson’s disease model).  
(24) 
(22) 
(23) 
(32) 
Skin 
 Skin aging is accelerated in the absence of Prx2 through ERK and JNK activation. 
 In TPA-induced skin inflammation, anti-inflammatory effects of PEP-1-Prx2 local application have been 
reported. This involves modulation of NF-κB and MAPK function. 
(28) 
(45) 
Lung 
 In ovalbumin-induced mouse asthma model, the absence of Prx2 increases the severity of asthma induction with a 
higher increase in bronchi thickness, mucus secretion and airway inflammation. Prx2 benefits asthma induction 
by reducing ROS levels, increasing BAFF expression and inhibiting TLR4 production. 
 In human idiopathic pulmonary fibrosis, Prx2 is weakly expressed in lung fibroblastic foci (FF) of IPF 
patients.  
(25) 
(26) 
Cardio-Vascular 
system 
 in Apolipoprotein E–deficient (ApoE−/−) mice, the absence of Prx2 accelerates plaque formation  and is associated 
with the activation of redox-dependent signalling molecules (p65, c-Jun, JNKs and p38 MAPK). In endothelial 
cells, Prx2 deficiency results in increased expression of v-CAM-1 and I-CAM-1, accumulation of immune cells 
(CD45
+
 cells, macrophages, and CD4
+
 cells) and increase TNF-α production in atherosclerotic lesions.  
 Prx2 exerts a preventive effect against platelet-mediated plug formation in a mouse model of FeCl3-induced 
carotid artery injury. Prx2
-/-
 mice show a pro-thrombotic phenotype after FeCl3-induced vascular injury. 
(18) 
(17) 
(46) 
Kidney 
 In rat models of glomerulosclerosis , studies show that Prx2 is expressed in podocytes and contributes to 
modulation of angiotensin mediated cell apoptosis via Akt signalling.  
 Studies in human subjects with renal cell carcinoma correlate the expression of Prx2 with the disease progression. 
(47) 
(48) 
Thymus 
 The absence of Prx2 is associated with thymus expansion, resulting in augmented number of thymocytes. This 
has been related to inefficient apoptosis, reduced number of CD4
+
/CD8
+
 T cells and increased level of ROS.  
(49) 
Immune response 
 Prx2 modulates immune cell-response by the scavenging ROS. Cell number and responsiveness of CD3+ T 
lymphocytes and dendritic cells are higher in the absence of Prx2. 
(50) 
VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; Bcl-2: B-cell lymphoma 2; Bax: BCL-2 like protein 4; ROS: reactive oxygen species; LPS: 
lipopolysaccharide;  NF-kB : nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α: tumor necrosis factor alpha; 6-OHDA: 6-hydroxydopamine; ASK1: apoptosis signal-
regulating kinase 1; JNK: c-Jun N-terminal kinases; HIF: Hypoxia-inducible factor; RBCs: red blood cells; Prx2: peroxiredoxin-2; PARP1:Poly [ADP-ribose] polymerase 1; ERK: extracellular 
signal–regulated kinases; TPA: 12-O-tetradecanoylphorbol-13-acetate; MAPK: mitogen-activated protein kinase; BAFF: B cell-activating factor; TLR: Toll-Like Receptor; IPF: idiopathic 
pulmonary fibrosis; v-CAM-1: Vascular cell adhesion molecule 1; I-CAM-1: Intercellular adhesion molecule 1. 
Oxidative stress and lung injury 
Studies on both acute lung injury (e.g. ALI) and chronic lung disorders such 
as chronic obstructive pulmonary disease (COPD) or pulmonary hypertension (PAH) 
have identified oxidative stress as key hub in lung damage and in disease progression. 
Lung is exposed more than other organs to high oxidant-mediated stress due to the 
presence of high oxygen extraction and direct contact with extra-body environment 
(e.g. pollution). Oxidizing agents can be produced endogenously by metabolic 
reactions during inflammatory response (such as activation of phagocytes, 
mitochondrial electron transport, NADPH oxidase system) or exogenously by 
cigarette smoking, pollution, radiation or drugs. Therefore, lung requires efficient 
antioxidant systems to limit local oxidation.  
In lung, different antioxidant systems are physiological expressed and 
required in lung homeostasis (Table 2).  Among them, superoxide dismutase (SOD) 
has been widely investigated (Table 2). SOD efficiently scavenges O2•− into H2O2. It 
is present in three forms: extracellular SOD (EC-SOD), copper/zinc-SOD (Cu/Zn-
SOD) and manganese-SOD (Mn-SOD). Lack of SOD promotes oxidant-induced lung 
damage. The overexpression of SOD has been shown to be protective against (i) 
hypoxia-induced PAH; (ii) endotoxin-induced ALI; (iii) allergen induced lung injury. 
SOD seems to limit oxidation and inflammation, improving vascular dysfunction. 
Furthermore, SOD modulates extracellular matrix remodeling in models of chronic 
hypoxia-induced PAH and idiopathic pulmonary fibrosis (Table 2). 
Other anti-oxidant systems such as catalase, glutathione peroxidase (Gpx), 
Peroxiredoxins (Prx1, 2, 3 and 6), thioredoxin and glutaredoxin (Grx) have been 
investigated in both acute or chronic lung injury (Table 2). These studies highlighted 
that (i) the absence of catalase promotes inflammation and fibrosis; (ii) Gpx and Grx 
levels are increased in various lung diseases (e.g. asthma, pulmonary sarcoidosis, 
allergic alveolitis, lung fibrosis); (iii) heme-oxygenase-1 (HO-1) degrades free heme 
and prevents heme-mediated severe local oxidation (Table 2). Finally, non-enzymatic 
molecules, such as vitamin C and E, glutathione and retinol have been reported to act 
as pulmonary antioxidants, scavenging oxygen free radicals (Table 2).   
Table 2. Anti-oxidant systems involved in acute and/or chronic lung damage 
Anti-oxidant system Results Refs 
Extracellular-SOD  
(EC-SOD) 
 Scavenges superoxide anion (O2•−) 
 Prevents oxidant-induced extra-cellular matrix degradation, abolishing the release of pro-fibrotic 
cytokine and the activation of TGF-β. In idiopathic pulmonary fibrosis (IPF), EC-SOD is low in fibrotic 
areas. 
 In neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia (BPD), the absence of EC-
SOD worsens PAH, disrupting VEGF/NO signalling pathway.  
 Selective loss of vascular EC-SOD promotes hypoxia-induced PAH. 
 Mice overexpressing EC-SOD exposed to hyperoxia show reduced neo-angiogenesis by scavenging 
induced free radicals. 
 Overexpression of EC-SOD prevents the development of hypoxia induced PAH. 
 EC-SOD overexpression decreases  the severity of endotoxin-induced acute lung injury (ALI). 
 EC-SOD overexpression attenuates chronic hypoxia-induced PAH, as supported by the reduction in   
vascular remodelling, small pulmonary vessels muscularization and collagen deposition. 
(51) (52) 
(53) (54) 
(55) (56) 
(57) (58) 
(59) 
copper/zinc-SOD  
(Cu/Zn-SOD) 
 Scavenges superoxide anion (O2
•−
)  
 In murine models of allergen-induced lung injury and asthma, Cu/Zn-SOD reduces lung injury.  
 Cu/Zn-SOD serum levels are increased in patients with idiopathic pulmonary fibrosis (IPF).  
(58) (59) 
(60) (61) 
(57) 
Manganese-SOD  
(Mn-SOD) 
 Scavenges superoxide anion (O2
•−
). 
 In extrinsic allergic alveolitis (EAA), pulmonary sarcoidosis and desquamative interstitial pneumonia 
(DIP), Mn-SOD reduces the local pulmonary damage. 
 Increased levels of Mn-SOD have been reported in alveolar epithelium from healthy smokers. 
 In rat lung, hyperoxia activates Mn-SOD and is associated with accumulation of inactive Mn-SOD.  
(58) (59) 
(57) (62) 
(63) (64) 
(65) 
 
Catalase 
 Scavenge hydrogen peroxide.  
 The expression of catalase is increased in; (i) alveolar regions of usual interstitial pneumonia (UIP); (ii) 
granulomas of sarcoidosis; (iii) extrinsic allergic alveolitis. These suggest a protective role of catalase 
against oxidation and inflammation leading to disease progression.  
 In human pulmonary fibrosis , reduced expression and activity of catalase have been reported. Catalase 
seems to play a protective role in mice exposed to bleomycin-induced inflammation. 
(58) (59) 
(63) (66) 
  
Glutathione peroxidase 
(Gpx) and Glutathione 
 Gpx protects alveolar epithelial cells against oxidative stress (e.g.: hyperoxia-induced lung damage). 
 Glutathione and glutathione peroxidase levels are increased in various granulomatous lung diseases (e.g.: 
chronic beryllium disease). 
 In sputum and plasma of IPF human subjects, glutathione content is reduced compared to healthy 
subjects. 
(58) (59) 
(58) (67) 
(68) 
Peroxiredoxin 
 Increased expression of different peroxiredoxins (Prx1, 3 and 6) has been reported in lung cancer, 
alveolitis and hypoxia induce lung injury. 
 Peroxiredoxin-2 is expressed by alveolar type II cells and is associated with activation of PDGF 
signaling pathway and cell proliferation. 
(58) (59) 
(69) (26) 
Thioredoxin 
 In patients with asthma attacks, thioredoxin serum level is increased compared to patients in remission.  
 Mice overexpressing thioredoxin and mice treated with human recombinant thioredoxin show decreased 
bleomycin-induced cellular infiltrates and fibrosis. 
(58) (59) 
(70) (71) 
(72) (73) 
Glutaredoxin  In allergic alveolitis, lung fibrosis and pulmonary sarcoidosis, glutaredoxin expression is reduced. 
(58) (59) 
(74) (75) 
Heme Oxygenase-1  
(HO-1) 
 Converts heme to carbon monoxide and billiverdin. 
 It is upregulated in smokers and in patients with cystic fibrosis, asthma, acute lung injury, and it is 
downregulated in severe chronic obstructive pulmonary disease. 
 Protective effects of HO-1 have also been suggested in patients with asbestosis or silicosis.  
 HO-1 is decreased in macrophages of  IPF patients. 
(58) (59) 
(76) (77) 
(78) 
Non-enzymatic 
antioxidants 
 In lung, vitamin C, vitamin D, vitamin E, beta carotene and retinol act as scavenger for both protein and 
lipid peroxidation. The revised studies underline that supplementation with vitamins or beta carotene is 
associated with improvement acute and  chronic lung diseases (e.g.: COPD)  through still partially 
known mechanism(s).   
 (59) (79) 
(80) (81) 
(82) (83) 
(84) (85) 
TGF-β: Transforming growth factor beta; PAH: pulmonary artery hypertension; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor; IPF: idiopathic 
pulmonary fibrosis; COPD: chronic obstructive pulmonary disease.  
Exogenous anti-oxidant molecules (e.g.: quercetin, rutin) have been evaluated 
in both acute and chronic lung diseases (86-88). Studies on rat models of several lung 
injuries have shown that N-Acetylcysteine (NAC) have beneficial effects on (i) 
monocrotaline-induced pulmonary hypertension (89); (ii) endotoxin induced-ALI 
(90); (iii) silica- induced lung fibrosis (91); (iv) ischemia-reperfusion lung injury (92).  
Chronic oxidative stress has been involved in the pathogenesis of two main 
chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and 
pulmonary artery hypertension (PAH) (93, 94). 
PAH is a chronic invalidating disorder, characterized by elevation of 
pulmonary arterial pressure combined with abnormality in vascular and extra matrix 
lung remodeling (95-97). Although in the last decade progresses have been made in 
the knowledge of PAH, much still remains to be investigated in the interplay between 
triggering factors and vascular dysfunctions in PAH. Three key factors have been 
identified to be important for development of PAH: (i) chronic inflammation, (ii) 
abnormal shear stress and (iii) hypoxia (98).  
The combination of chronic inflammation and chronic hypoxia promotes 
structural changes in the pulmonary vascular bed such as pulmonary artery 
muscolarization, increased medial thickness and deposition of matrix components 
(e.g. collagen, elastan). The biocomplexity of PAH is further increased by the 
contribution of chronic inflammation plus abnormal shear stress that promote: (i) 
vascular endothelial cell damage; (ii) local reduction of vasodilator(s) (e.g. nitric 
oxide or prostacyclin); (iii) local increased of vasoactive mediators, promoting 
vascular remodeling (ET-1, PDGF, TGF-β, VEGF); and (iv) increased expression of 
vascular adhesion molecules (e.g. v-CAM-1, I-CAM-1) (98-102). Thus, these factors 
synergize and promote a high pro-oxidant environment, which requires efficient local 
anti-oxidant system to prevent or delay the development of PAH (103).  
Previous studies have shown that the disruption of the local 
oxidant/antioxidant balance is a key step in development of severe chronic pulmonary 
damage (95). This is also supported by evidences in mouse models lacking 
extracellular superoxide dismutase (EC-SOD), which displays hypoxia-induced 
severe pulmonary hypertension (54) (see also Table 2). Treatment with exogenous 
anti-oxidants such as NAC or quercetin or rutin has been proposed to limit oxidation 
that sustains the development of PAH. However, the beneficial effects of these anti-
oxidants seem to be strictly dependent on the timing of the starting dose with respect 
to disease severity and to the possibility to affect the disease natural history. 
In this scenario, autophagy is an efficient process used by stressed cells to 
clear intracellular damaged proteins and organelles. Growing evidences link 
oxidation to autophagy in different cell model. The slow removal of damaged 
proteins might drive cell to apoptosis (104, 105). Some of the autophagy related 
proteins (Atg) are redox-sensitive proteins and might be either directly modulated by 
ROS (e.g.: Atg4 or Atg7) or transcriptionally regulated by oxidative stress (e.g.: p62) 
(104, 106-108). The functional connection between ROS and autophagy is also 
supported by the improvement of autophagy promoted by exogenous anti-oxidants, 
such as NAC (104, 106).  
The connection of autophagy with the development of pulmonary diseases is 
highlighted by data on mouse models lacking Atg proteins. Atg7-/- or Atg5-/- mice 
develop spontaneous lung inflammation characterized by increased lung 
inflammatory infiltrate and extracellular matrix remodeling with collagen deposition 
(109). In addition, it has been shown that the loss of Atg7 promotes endothelial-to-
mesenchymal transition associated with upregulation of the pro-fibrotic TGFβ 
signaling pathway (110). In vivo, this results in increased lung collagen deposition 
and higher susceptibility to bleomycin-induced pulmonary fibrosis (110). Atg4b-
deficient mice also display increased sensitivity to bleomycin-induced lung injury 
with (i) apoptosis of alveolar and bronchiolar epithelial cells, (ii) inflammation and 
(iii) extensive lung fibrosis (111). Collectively, these studies indicate that autophagy 
participates to lung protection against oxidation and inflammation.  
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ABSTRACT 
Pulmonary-artery-hypertension (PAH) is a life-threatening and highly invalidating chronic 
disorder. Chronic oxidation contributes to lung damage and disease progression. 
Peroxiredoxin-2 (Prx2), a typical 2-cysteine (Cys) peroxiredoxin, is able to efficiently 
scavenge low concentration of H2O2, but its role on lung homestasis is yet to be fully 
defined. Here, we showed that Prx2-/- mice displayed chronic lung inflammatory disease 
associated with (i) abnormal pulmonary vascular dysfunction; and (ii) increased markers of 
extracellular-matrix remodeling.  Hypoxia was used to induce PAH. We focused on the 
early phase PAH to dissect the role of Prx2 in generation of PAH. Hypoxic Prx2-/-mice 
showed (i) amplified inflammatory response combined with cytokine storm; (ii) vascular 
activation and dysfunction; (iii) increased PDGF-B lung levels, used as marker of 
extracellular-matrix deposition and remodeling; and (iv) autophagy activation. Rescue 
experiments with in vivo the administration of fused-recombinant-PEP-Prx2 to hypoxic 
mice show a reduction in pulmonary inflammatory vasculopathy and down-regulation of 
autophagy. Thus, we propose Prx2 plays a pivotal role in the early stage of PAH as 
multimodal anti-oxidant system targeting oxidation, inflammatory vasculopathy and 
indirectly autophagy. Collectively, our data indicate that the potentiation of endogenous 
anti-oxidant systems might interrupt the oxidation related vicious circle involved in the 
pathogenesis of PAH.   
 
 
 
 
 
 
Key words: peroxiredoxin-2, chronic hypoxia, autophagy 
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INTRODUCTION  
Pulmonary artery hypertension (PAH) is a life threatening highly invalidating chronic 
disorder [1-3]. Although in the last decade progresses have been made in the 
identifications of factors involved in its pathogenesis, much still remains to be investigated 
in the mechanism involved in the early stage of PAH [3-5]. Regardless of the initial event, 
the combination of chronic inflammation and chronic hypoxia promote a high pro-oxidant 
environment, mediating disease progression [1, 2, 4, 6, 7]. Thus, endogenous antioxidant 
systems controlling oxidation serve also as downstream regulator of autophagic process. 
Studies in vivo in animal model of PAH have shown that the absence of endogenous anti-
oxidant such as superoxide dismutase- 1 (SOD-1) or cytoprotective systems such as 
heme-oxygenase 1 (HO-1) accelerates the development of PAH [8-11]. 
 In this scenario, an efficient catabolic pathway to clear intracellular damaged 
proteins is required. In different cell models, growing evidences link ROS to autophagy, 
priming cells to better tolerate oxidation [12, 13]. In addition, some autophagy related 
proteins (Atg) are redox-sensitive proteins and might also be functionally modulated by 
ROS [13, 14].  
Prx2 is a typical 2-cysteine (Cys) peroxiredoxin, which is able to efficiently 
scavenge low concentration of H2O2 without inactivation due to over-oxidation. Studies in 
mouse genetically lacking Prx2 (Prx2-/-) have highlighted its protective role against LPS 
induced lethal shock and acute distress syndrome (ARDS) [15-21]. In addition, in vitro and 
in vivo model of ischemic/reperfusion stress highlighted the key role of Prx2 as anti-
oxidant and cytoprotective system [22, 23].  
Here, we studied the role of Prx2 in development of pulmonary hypertension in mice 
genetically lacking Prx2 (Prx2-/-), using hypoxic stress to explore the early stage of early 
phase of pulmonary hypertension. Our data collectively indicate that Prx2 plays a key role 
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against oxidation in the early phase of hypoxia induced pulmonary hypertension. The 
recombinant PEP fused Prx2 (PEP Prx2) corrects the imbalance between oxidants/anti-
oxidants during hypoxic stress by (i) reducing local and systemic inflammation; (ii) 
preventing vascular activation and PDGF-B up-regulation and (iii) down-regulating 
autophagy activation in response to hypoxia. Thus, PEP Prx2 might represent an 
interesting new multimodal therapeutic option in the early stage PAH.  
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MATERIALS AND METHODS 
Drugs and chemicals. Details are reported in Supplemental Materials and Methods. 
Mouse strains and design of the study. C57B6/2J mice as wildtype controls (WT) and 
Prx2-/- mice aged between 4-6 months both male and female were used in the present 
study [16, 24].  The Institutional Animal Experimental Committee, University of Verona 
(CIRSAL) and by the Italian Ministry of Health approved the experimental protocols. 
Where indicated WT and Prx2-/- mice were treated with 1) N-Acetyl-Cysteine (NAC) at the 
dosage of 100 mg/Kg/d (in NaCl 0.9%, NaOH 36 mM, pH 9.4; ip) or vehicle only for 3 
weeks [16, 18]; 2) PEP Prx2 (in PBS) or vehicle at the dosage of 3 mg/Kg/d ip or vehicle 
for 4 weeks before and during hypoxia [16]. Whenever indicated, mice were exposed to 
hypoxia (8% oxygen for 10 hours, 3 days, 7 days) (Hy) as previously described [25-27]. To 
collect organs, animals were first anesthetized with isofluorane, bronchoalveolar lavage 
(BAL) was collected and then mice were euthanized. Organs were immediately removed 
and divided into two and either immediately frozen in liquid nitrogen or fixed in 10% 
formalin and embedded in paraffin for histology. 
Bronchoalveolar lavage (BAL) measurements. BAL fluids were collected and cellular 
contents were recovered by centrifugation and counted by microcytometry as previously 
reported [25]. Percentage of neutrophils was determined on cytospin centrifugation. 
Remaining BAL samples were centrifuged at 1,500 x g for 10 min at 4°C. The supernatant 
fluids were used for determination of total protein content [25].   
Lung molecular analysis 
Lung histology. Multiple (at least five) three micron whole mount sections were obtained 
for each paraffin-embedded lung and stained with hematoxylin eosin, Masson’s trichome, 
and May-Grünwald-Giemsa.  α-smooth muscle actin immunohistochemistry (IHC) on lungs 
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was carried out as previously reported [25, 28]. Lung pathological analysis was carried out 
by blinded pathologists as previously described [25, 28]. Based on previous reports (18, 
38), the pathological criteria for lung histopatholgy were as follows: i) Bronchus: Mucus: 0: 
no mucus; +: mucus filling less than 50% of the area of the bronchus section; ++: mucus 
filling more than 50% of the area of the bronchus section. (ii) Inflammatory infiltrate 
density: 0: less than 5 inflammatory cells per field; +: 5-30 inflammatory cells per field; ++ 
more than 30 inflammatory cells per field. (iii) Thrombi: 0: no thrombus; + presence of a 
thrombus in one field, at magnification 250.  
Immunoblot analysis. Frozen lung and heart from each studied group were homogenized 
and lysed with iced lyses buffer (LB containing: 150 mM NaCl, 25 mM bicine, 0.1% SDS, 
Triton 2%, EDTA 1 mM, protease inhibitor cocktail tablets (Roche), 1 mM Na3VO4 final 
concentration) then centrifuged 10 min at 4°C at 12,000 g. Proteins were quantified and 
analysed by mono-dimensional SDS polyacrylamide gel electrophoresis. Gels were 
transferred to nitrocellulose membranes for immuno-blot analysis with specific antibody. 
Details are reported in Supplemental materials and Methods [25, 29].  
RNA isolation, cDNA preparation and quantitative RT-PCR. Total RNA was extracted 
from tissues using Trizol reagent (Life Technologies, Monza, Italy). Synthesis of cDNA 
from total RNA (1μg) was performed using Super Script II First Strand kits (Life 
Technologies). Quantitative RT-PCR (qRT- PCR) was performed using the SYBR-green 
method, following standard protocols with an Applied Biosystems ABI PRISM 7900HT 
Sequence Detection system. Relative gene expression was calculated using the 2(-ΔCt) 
method, where ΔCt indicates the differences in the mean Ct between selected genes and 
the internal control (GAPDH). qRT-PCR primers for each gene were designed with Primer 
Express 2.0 (Life Technologies) (primer sequences are reported in Table 1S) [25, 28]. 
MDA assay. MDA was determined as previously reported [30].   
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Evaluation of right ventricular hypertrophy and echocardiography measurements. 
Hearts were fixed with 10% formaldehyde for 24 hours. The right ventricular (RV) free wall 
was separated from the left ventricular with septum (LV+S) under dissection microscope. 
RV and LV+S were separately weighed and used to calculate the ratios RV/(LV+S)/body 
weight [31]. Transthoracic echocardiography was performed with a Vevo 2100 
echocardiograph (Visual Sonics, Toronto, Canada) equipped with a 22-55 MHz transducer 
(MicroScan Transducers, MS500D) as previously reported [25]. 
Statistical analysis. Data were analyzed using either t-test or the 2-way analysis of 
variance (ANOVA) for repeated measures between the mice of various genotypes. A 
difference with a P value less than 0.05 was considered significant.  
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RESULTS 
Mice genetically lacking Prx2 show lung inflammation, increased pulmonary 
vascular activation and extracellular-matrix remodeling  
Under normoxia Prx2-/- mice show increased peribronchial oedema without changes in the 
number of mucus cells (Fig. 1A, upper panel). The systematic study for α-smooth cells 
expression showed a staining in broken line only on bronchial sections of Prx2-/- mice, 
suggesting an initial pulmonary vessel muscularization in the absence of Prx2 (Fig. 1A, 
lower panel). The analysis of bronchoalveolar lavage (BAL) revealed increased levels of 
proteins and of total leukocytes in Prx2-/- mice compared to wildtype, indicating an 
abnormal pulmonary vascular leakage (Fig. 1B).  
In Prx2-/- mice, we found increased active form of NF-kB and Nrf2, two redox related 
transcriptional factors, compared to wild-type animal (Fig. 1C; Fig. 1SA). This was 
associated with increased lung MDA levels (Fig. 1SB) and up-regulation at mRNA levels of 
cytokines such as IL-6, IL-1b and IL10, known targets of NF-kB (Fig. 1D). We confirmed 
the increased expression of IL-6 in lung from Prx2-/- mice compared to wildtype animals 
(Fig. 1E, Fig. 1SC). In addition, in Prx2-/- mice, we observed increased expression of two 
cytoprotective systems related to Nrf2 activity: HO-1, a vascular and lung cytoprotector, 
and SOD-1, a potent anti-oxidant enzyme [32]. This was associated with higher levels of 
(i)  endothelin-1 (ET-1), the most potent vasoconstrictive and bronchoconstrictive cytokine 
[28]; (ii) VCAM-1, a marker of vascular endothelial activation [25]; and (iii) PDGF-B, a 
known factor involved in lung extra-cellular matrix remodeling [33] (Fig. 1E; Fig. 1SC). 
These data link the absence of Prx2 with persistent lung inflammation, endothelial 
vascular activation, and extracellular matrix remodeling.  
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Prolonged hypoxia promotes the development of early stage pulmonary 
hypertension in Prx2-/- mice  
Based on our previous report, showing the development of early stage PAH in a 
mouse model for sickle cell disease but not in wildtype mice [31], we exposed both mouse 
strains to hypoxia (Hy) 8% oxygen for 7 days.  As shown in Fig. 2A, hypoxia induced 
sparse inflammatory cell infiltrate with some peribronchial oedema in Prx2-/- mice. On the 
bronchial epithelium there was no significant change in the number of mucus cells in both 
mouse strains. On vascular sections, no thrombus was found in any of the mouse groups. 
The systematic study for α-actin deposition revealed the presence of almost linear staining 
around bronchial and vascular sections in Prx2-/- mice (Fig. 2A, lower panel). While, α-
actin depositions were sparse in hypoxic wildtype mice. 
 We evaluated the presence of RV hyperthrophy in both mouse strains exposed to 
7days hypoxia. In Prx2-/- mice, we observed a slight but significant increase in RV/(LV+S) 
ratio (normoxia: 0.21±0.03 vs hypoxia 0.34±0.05; n=6, P<0.05), whereas no changes were 
observed in wildtype mice in agreement with our previous report [31]. This was associated 
with a significant increase in mitral valve deceleration time and a reduction in pulmonary 
acceleration time/ ejection time ratio (Fig. 2B), indicating early diastolic dysfunction and 
increased right ventricular systolic pressure in Prx2-/- mice. In addition, we found hypoxia 
induced increased expression of SOD-1 in heart from both mouse strains, but to a higher 
extent in Prx2-/- mice (Fig. 1SD). Hypoxia induced up-regulation of (i) VCAM-1 and ICAM-
1; and (ii) atrial natriuretic peptide (ANP) was also observed in both mouse strains (Fig. 
1SD). 
Our findings are consistent with the development of early stage of PAH promoted 
by severe oxidation and amplified inflammatory response in Prx2-/- mice exposed to 7 days 
hypoxia.  
Prx2 plays an important role as cytoprotective system against hypoxia induced PAH   
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In order to follow-up the generation of PAH in Prx2-/- mice, we studied both mouse 
strains at different time intervals between 0 to 7 days hypoxia to identify the optimal 
window-time to analyze mechanism(s) involved in development of PAH. BAL protein and 
leukocyte count were significantly increased in Prx2-/- mice during hypoxia at 10 hours, 3 
days and 7 days compared to wildtype animals (data not shown).  
Hypoxia markedly increased Prx2 expression in lung from wildtype mice at 10 
hours, 3 days and 7 days of exposure (Fig. 2C; Fig. 2SA). This was associated with time 
dependent increased expression of the Prx2 repairing systems: sestrin-2 and thioredoxin-
reductase (Trdx; Fig. 2C; Fig. 2SA). The modulation of Trdx expression during hypoxia 
even in the absence of Prx2, one of its main functional targets, may be possible related to 
the fact that Trdx is part of different NADPH-dependent pathways [16, 34].  
In Prx2-/- mice exposed to hypoxia, we observed a rapid and sustained activation of 
Nrf2 in response to hypoxia, while there was a reduction in activation of NF-kB (Fig. 2D, 
2SB). Otherwise, wildtype mice showed an early response of Nrf2 at 10 and 3 hours 
hypoxia, partially overlapping the activation of NF-kB observed at 3 and 7 days hypoxia 
(Fig. 2D, 2SB). These data suggest that Nrf2 might be a precocious back-up mechanism 
in response to hypoxia, which is early activated in both mouse strains, but to higher extent 
in mice genetically lacking Prx2. 
Since pro-inflammatory cytokines are modulated by oxidation and participates to the 
development of PAH [3, 35, 36], we evaluated IL1b and IL6 expression in lung from both 
mouse strains during hypoxia. In Prx2-/- mice, IL-1b mRNA levels were significantly 
increased at 3 days of hypoxia compared to wildtype animals, which displayed increased 
IL-1b expression only at 7 days hypoxia (Fig. 3A).  In Prx2-/- mice, lung IL-6 mRNA 
expression was significantly upregulated at 3 days of hypoxia followed by a decreased at 7 
days of hypoxia to levels still higher than those observed in wildtype mice (Fig. 3B). These 
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data support an earlier and amplified inflammatory response in Prx2-/- mice in response to 
hypoxia compared to wildtype animals.    
 We then evaluated markers of pulmonary vascular remodeling (ET-1, PDGF-B, 
ANP) and vascular endothelial activation (VCAM-1 and ICAM-1). As shown in Fig. 3C, ET-
1 expression was increased in both mouse strains but to a higher extent in Prx2-/- mice 
compared to wildtype; while PDGF-B levels increased earlier, reaching higher and 
constant levels in Prx2-/- mice compared to wildtype during hypoxia. VCAM-1 and ICAM1 
expression was similarly increased in both mouse strains at 7 days hypoxia (Fig. 3D). 
Whereas, ANP expression was higher in Prx2-/- mice than in wildtype exposed to 
prolonged hypoxia (Fig. 3D).   
Collectively, these data indicate that the absence of Prx2 accelerates vascular activation 
and extra-matrix remodeling, amplifying inflammatory response during hypoxia.   
PEP Prx2 treatment rescues prolonged hypoxia induced heart and lung 
inflammatory vasculopathy  
To address the question whether Prx2 plays a role in lung chronic inflammatory 
disease, we firstly evaluated the impact of recombinant fusion protein PEP Prx2 
(1.5mg/Kg/day ip, 3weeks) to both mouse strains under room air condition. In normoxic 
Prx2-/- mice, PEP Prx2 treatment (i) prevented Nrf2 and NF-kB activation (Fig. 3SA); (ii) 
reduced HO-1 protein expression (Fig. 3SB); and (iii) decreased the levels of ET-1, 
VCAM-1 and PDGF-B (Fig. 3SB). No major changes were observed in wildtype animals 
(Fig. 3SA, 3SB).  
In Prx2-/- mice exposed to 7 days hypoxia, PEP Prx2 treatment significantly reduced the 
hypoxia mediated diastolic dysfunction and ameliorated RVSP, as suggested by the 
increased in PAT/ET ratio (Fig. 4A, 4SA). In agreement, in heart from PEP Prx2 treated 
Prx2-/- mice exposed to 7 days hypoxia, we found a reduction of ANP expression as well 
as of markers of vascular endothelial activation (Fig.4B, 4SB). This was associated with a 
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decrease in levels of SOD-1 and in the oxidation state of proteins from heart of hypoxic 
Prx2-/- mice treated with PEP Prx2 (Fig. 4SC). We found similar evidences of the beneficial 
effects of PEP Prx2 on lung from Prx2-/- mice exposed to prolonged hypoxia. As shown in 
Fig. 4C, PEP Prx2 promoted a significant reduction in hypoxia induced increase of ANP, 
VCAM-1, ICAM-1 and PDGF-B levels compared to vehicle treated Prx2-/- animals.      
In order to evaluate whether the effects of PEP Prx2 treatment were specific of Prx2 
or related to a general anti-oxidant effect, we treated both mouse strains with NAC (100 
mg/kg/day for 3 weeks), a known anti-oxidant agent previously used in other in vitro and in 
vivo models of PAH [6, 37]. No changes were present in the levels of Nfr2 and NF-kB 
activation in Prx2-/- mice treated with NAC, suggesting that the effects of PEP Prx2 are 
peculiar of Prx2 and not only related to its general antioxidant effects (data not shown).  
To test the role of Prx2 in development of PAH, we chose to further study Prx2-/- 
mice at day 3 of hypoxia, when we expect to be the turning point in the imbalance between 
oxidation/ anti-oxidant activities based on the increased of Prx2 in wild-type mice (Fig. 2C) 
and the activation of redox-related transcriptional factors (Fig. 2D).  
In Prx2-/- mice, PEP Prx2 prevents the hypoxia induced oxidative stress and reduces 
inflammatory vascular activation and extracellular matrix remodeling  
As shown in Fig. 5A, PEP Prx2 treatment prevented the hypoxia induced increased in BAL 
protein and leukocyte content in both mouse strains. This was associated with a marked 
reduction in protein oxidation state in both mouse strains exposed to 3 days hypoxia and 
treated with PEP Prx2, supporting the local anti-oxidant effect of exogenous PEP Prx2 
treatment during hypoxia stress (Fig. 5B). In agreement, we found that PEP Prx2 
administration prevented the hypoxia induced Nrf2 and NF-kB activation in both mouse 
strains (Fig. 5C, 5SA). This was paralleled by the reduction in HO-1, IL-6, ET-1, VCAM-1 
and PDGF-B (Fig. 6A, 5SB-C).  
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These data suggest that PEP Prx2 treatment during hypoxia is able to (i) decrease local 
pulmonary inflammation and oxidation, (ii) reduce systemic inflammatory response; (iii) 
beneficially affect hypoxia abnormalities in pulmonary vascular leakage; and (iv) prevent 
hypoxia activation of redox-sensitive transcriptional factors Nrf2 and NF-kB.  
PEP Prx2 down-regulates autophagy in Prx2-/- mice exposed to hypoxia 
Autophagy has been recently linked to cellular oxidation and transition of smooth muscle 
cells in response to PDGF-B [12, 38]. In mice exposed to 3 days hypoxia, we evaluated 
key elements of autophagy machinery and the effects of PEP Prx2 treatment. Based on 
revision of the literature, we chose to analyze the expression of (i) autophagy related 
proteins ULk1 that is required for initiation of autophagy; (ii) LC3 I/II, a coordinator of 
phagosomal membranes and (iii) p62, a key cargo protein and component of inclusion 
bodies; and (iv) pro-caspase 3/caspase 3, involved in digestion of damaged proteins [13, 
39-41].   
As shown in Fig. 6B, normoxic Prx2-/- mice showed increased LC3-II formation associated 
with increased expression of Ulk1 and p62 compared to wildtype mice (see also Fig. 5SA). 
This was associated with higher expression of pro-caspase 3/caspase 3, indicating an 
activation of autophagy to clear intracellular oxidative damaged proteins in Prx2-/- mice. 
In both mouse strains, hypoxia markedly activated autophagy as supported by increased 
LC3I/II expression, consumption of Ulk1 and reduction of p62, suggesting a clearance of 
p62 positive inclusion bodies containing damaged proteins (Fig. 6B, 6S). It is of note that 
the pro-caspase/caspase 3 ratio was also increased in both mouse models exposed to 
hypoxia, but to higher extent in Prx2-/- mice compared to wildtype (Fig.6B, 6S).  
As a proof of concept that Prx2 is important in the crossroad between hypoxia induced 
oxidation and autophagy, we evaluated the effects of PEP Prx2 treatment on autophagy in 
mice exposed to 3 days hypoxia. As shown in Fig. 6B, PEP Prx2 administration rescued 
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the hypoxia induced activation of autophagy, indicating that Prx2 acts as multimodal anti-
oxidant system (see also Fig. 6S).  
 
DISCUSSION 
 
Here, we firstly show the novel role of Prx2 as lung cytoprotector against hypoxia 
induced PAH.  Our data also indicate that Prx2 is required in management of the 
physiologic oxidation in lung. In fact, under room air condition In Prx2-/- mice show we lung 
chronic inflammatory vasculopathy and vascular dysfunction, associated with activation of 
extra-matrix remodeling (Fig.1). This is in agreement with previous studies in mouse 
models genetically lacking other anti-oxidant systems such as SOD-1, which show 
increased susceptibility to both acute and chronic lung injury [8, 42, 43].  
Prx2-/- mice exposed to prolonged hypoxia developed signs of PAH, combined with 
inflammatory vasculopathy and increased in PDGF-B as marker of extra-matrix 
remodeling on both lung and heart site. We found a significant increase in ANP lung and 
heart levels in both mouse strains exposed to hypoxia, but again to a higher extent in Prx2-
/- mice. This indicates an attempt of endogenous system to induce pulmonary vaso-
relaxation and to modulate lung and heart remodeling in response to hypoxia [44, 45]. 
Since hypoxia promotes oxidative stress, we evaluated the behavior of two key 
redox-related transcriptional factors, Nrf2 and NF-kB in both mouse srtains during hypoxia. 
Nrf2 was early activated in both mouse strains, but to a higher extent in Prx2-/- mice 
compared to wildtype animals (Fig. 2). Whereas, NF-kB seems to be more important in 
prolonged hypoxia for wildtype mice compared to Prx2-/- animals. These data support the 
early activation of Nrf2 as back-up mechanism against severe oxidation in mice genetically 
lacking Prx2 [16].  
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The rescue experiments with PEP Prx2 in Prx2-/- mice exposed to prolonged 
hypoxia corroborate the importance of Prx2 in the functional cascade activated in 
response to hypoxia. The evidences in Prx2-/- mice undergoing to 3 days hypoxia further 
support the pivotal role of Prx2 in lung homeostasis.  
In this scenario, autophagy becames an important mechanism in the cross-road 
between hypoxia and oxidation. In fact, autophagy is a cytoprotective process against 
oxidation and hypoxia induced cellular damage, but it also protects hypoxia induced 
hyperproliferating cells (i.e.: vascular cells and fibroblasts), which are involved in vascular 
and extracellular matrix remodeling [13, 46-48]. Our data on autophagy highlight the janus 
bifront behavior of defensive autophagy in lung of Prx2-/- mice exposed to hypoxia. In Prx2-
/- mice, we found activation of autophagy already under normoxia, possibly related to the 
impairment of endogenous anti-oxidant system due the absence of Prx2. Hypoxia induced 
a further activation of autophagy in Prx2-/- mice, which also displayed high levels of PDGF-
B, promoting extra-matrix remodeling and alpha actin-deposition. The redox-related 
trascriptional factor Nrf2 has been recently linked to autophagy through p62 to ensure cell 
survival against severe oxidation [13, 46]. Indeed, the treatment with PEP Prx2 reduced 
Nrf2 activation and switched-off autophagy as supported by the reduction in LC3II and 
accumulation of p62 (fig. 6). Previous studies have shown the partial effect of NAC, an 
exogenous anti-oxidant, in modulating autophagy in chronic lung disease [14]. Here, we 
found that PEP Prx2 potentiates the endogenous anti-oxidant system during hypoxia, with 
a multimodal action targeting: inflammatory response, cytokine storm, vascular and 
extracellular matrix remodeling (Fig. 6C). The correction of the imbalance between 
oxidation and anti-oxidant systems might interrupt the vicious circle, established between 
oxidation-chronic inflammation and chronic activation of autophagy towards the generation 
of PAH (Fig. 6C).  
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In conclusion, we have firstly highlighted the novel pivotal role of Prx2 in preventing 
PAH induced by hypoxia. The high bio-complexity of PAH requires multimodal therapeutic 
approaches, which simultaneously act on different targets involved in its pathogenesis. 
Our data collectively support a rationale for considering the potentiation of endogenous 
anti-oxidant systems, such as Prx2, as novel therapeutic option in treatment of the early 
phase of PAH. 
 
ABBREVIATIONS 
PAH: pulmonary arthery hypertension; PBS: phosphate buffer; (qRT)-PCR: quantitative 
real time; ARDS:  acute respiratory distress syndrome; ARE: anti-oxidant responsive 
element; Atg4: autophagy related 4; BAL: bronchoalveolar lavage; ET-1: endothelin 1; 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HO-1: heme oxygenase 1; HY 
stress: hypoxia/reoxigenation stress; IL-1b: interleukin 1b; IL-6: interleukin 6; IL-10: 
interleukin 10; LPS: lipopolysaccharides; NAC: N-acetyl-cysteine; NF-kB: nuclear factor 
kappa-light-chain-enhancer of activated B cells; Nrf2: nuclear factor-erythroid 2; PAH: 
pulmonary artery hypertension; PDGF-B Platelet-derived growth factor subunit B; PEP 
Prx2: Prx2 fused to cell penetrating carrier PEP1 peptide; Prx2: peroxiredoxin-2; ROS: 
reactive oxygen species; SMCs: smooth muscle cells; SOD-1: superoxide dismutase 1; 
Trdx: Thioredoxin reductase; VCAM-1: vascular cell adhesion molecule 1; MDA: 
malondialdehyde; RV: right ventricular; RVSP: right ventricular systolic pressure; PAT: 
pulmonary acceleration time; ET: ejection time; ICAM-1: intercellular adhesion molecule 1; 
ANP: atrial natriuretic peptide; Ulk 1: Serine/threonine-protein kinase Ulk1; LC3 I/II: 
microtubule-associated protein 1A/1B-light chain 3 
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FIGURE LEGENDS 
Fig. 1. The absence of Prx2 promotes lung inflammation, increased pulmonary 
vascular activation and extra-matrix remodeling markers. A. Comparison of Prx2-/- 
with WT mice shows an increased peribronchial edema in Prx2-/- mice (upper panel 
Hematoxylin Eosin x250) and deposits of alpha actin in vascular walls in Prx2-/- mice 
(lower panel Immunohistochemistry using anti alpha actin antibody x 600). B. Upper 
panel. BAL protein content from wildtype (WT) and Prx2-/- mice under normoxic condition. 
Data are presented as means± SD (n=6; *p<0.05 compared to WT mice). Lower panel. 
BAL leukocyte content from wildtype (WT) and Prx2-/- mice under normoxic condition. Data 
are presented as means± SD (n=6; *p<0.05 compared to WT mice). C. Immunoblot 
analysis with specific antibodies against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 
(P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2-/- mice under normoxic condition.  
One representative gel from six with similar results is presented. Densitometric analysis of 
immunoblots is shown in Fig. 1SA. D. IL-6, IL-1B , IL-10 mRNA levels in lung tissues 
(normalized to GADPH) from WT and Prx2-/- mice. * p <0.05 (WT vs Prx2-/-). Each sample 
(WT; Prx2-/-) is a pool from 5 mice. Representative of three independent experiments. E. 
Immunoblot analysis with specific antibodies against IL-6, heme-oxygenase 1 (HO-1), 
endothelin-1 (ET-1), superoxide dismutase (SOD-1), vascular cell adhesion molecule-1 
(VCAM-1), platelet derived growth factor-B (PDGF-B) and peroxiredoxin-2 (Prx2) of lung 
from wildtype (WT) and Prx2-/- mice under normoxic condition.  One representative gel 
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from six with similar results is presented. Densitometric analysis of immunoblots is shown 
in Fig. 1SC. 
Fig. 2. In Prx2-/- mice, hypoxia induces early stage pulmonary hypertension and is 
associated with activation of redox-related transcriptional factors. A. Comparison of 
Prx2-/- with WT mice shows a sparse inflammatory infiltrate and an increased peribronchial 
edema in Prx2-/- mice (upper panel Hematoxylin Eosin x250) and deposits of alpha actin in 
vascular walls in Prx2-/- mice (lower panel Immunohistochemistry using anti alpha actin 
antibody x 600). B. Representative images of mitral inflow pattern recorded by Doppler 
echo imaging in wildtype (WT) and Prx2-/- mice under hypoxia as in Fig. 1A. Lower 
panels. Average mitral valve deceleration time (left panel) and pulmonary acceleration 
time (PAT) to ejection time (ET) ratio (right panel). *p<0.05 and **p<0.01 WT vs Prx2-/- 
mice; #p<0.05 and ##p<0.01 hypoxia vs basal by one-way ANOVA followed by Newman-
Keuls Multiple Comparison test. C. Immunoblot analysis with specific antibodies against 
peroxiredoxin-2 (Prx2), sestrin-2 and thioredoxin-reductase 1 (Trdx) of lung wildtype (WT) 
and Prx2-/- mice under normoxia (N) exposed to hypoxia) for 10 hours (10 h), 3 days (3D), 
7 days (7D).  One representative gel from six with similar results is presented. 
Densitometric analysis of immunoblots is shown in Fig. 2SA. D. Immunoblot analysis with 
specific antibodies against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and 
Nrf2 of lung wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia 
(Hy) for 10 hours (10 h), 3 days (3D), 7 days (7D).  One representative gel from six with 
similar results is presented. Densitometric analysis of immunoblots is shown in Fig. 2SB. 
Fig. 3. In Prx2-/- mice, hypoxia is associated with amplified inflammatory response, 
vascular activation and increased expression of PDGF-B, a marker of extracellular 
matrix remodeling. A-B. IL-1b (A) and IL-6 (B) mRNA levels in lung tissues (normalized 
to GADPH) wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 
10 hours (10 h), 3 days (3D), 7 days (7D). *p<0.05 compared to wildtype; ^ p value <0.05 
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compared to normoxic mice. Each sample is a pool from 5 mice. Representative of three 
independent experiments. C. Upper panel. Immunoblot analysis with specific antibodies 
against endothelin-1 (ET-1) and platelet derived growth factor-B (PDGF-B) of lung from 
wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxia for 10 hours 
(10 h), 3 days (3D), 7 days (7D).  One representative gel from six with similar results is 
presented. Lower panel. Relative quantification of immunoreactivity of ET-1 and PDGF-B 
in lung from wildtype (WT) and Prx2-/- mice under normoxia (N) and exposed to hypoxiafor 
10 hours (10 h), 3 days (3D), 7 days (7D). Data are shown as means ±SD (n=6). *p<0.05 
compared to wildtype; ^ p<0.05 compared to normoxic mice. The grey area highlights the 
changes in the ET-1 and PDGF-B expression in the mouse strains at 3 days hypoxia. D. 
Upper panel. Immunoblot analysis with specific antibodies against atrial natriuretic 
peptide (ANP), vascular adhesion molecule -1 (VCAM-1) and intracellular adhesion-
molecule- 1 (ICAM-1) of lung from wildtype (WT) and Prx2-/- mice under normoxia (lane 1 
and 2) and exposed to 7 days (7D) hypoxia.  One representative gel from six with similar 
results is presented. Lower panel. Relative quantification of immunoreactivity of ANP, 
VCAM-1, ICAM-1 in lung from wildtype (WT) and Prx2-/- mice under normoxia and 
exposed to 7 days (7D) hypoxia. Data are shown as means ±SD (n=6). *p<0.05 compared 
to wildtype; ^ p<0.05 compared to normoxic mice. 
Fig. 4. The administration of PEP Prx2 prevented the hypoxia induced diastolic 
dysfunction and increased right ventricular pressure with associated reduction in 
heart/lung oxidation and vascular endothelial activation. A. Average mitral valve 
deceleration time (left panel) and pulmonary acceleration time (PAT) to ejection time (ET) 
ratio (right panel); *p<0.05 vehicle treated Prx2-/- mice vs PEP Prx2 treated Prx2-/- mice; by 
one-way ANOVA followed by Newman-Keuls Multiple Comparison test. Representative 
images of mitral inflow pattern recorded by Doppler echo imaging in Prx2-/- mice treated 
with PEP Prx2 are shown in Fig. 4SA. B. Immunoblot analysis with specific antibodies 
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against atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), 
intracellular adhesion-molecule- 1 (ICAM-1) and superoxide dismutase-1 (SOD-1) of heart 
from Prx2-/- mice  under normoxia (lane 1) and exposed to 7 days (7D) hypoxia treated 
with either vehicle or PEP Prx2.  One representative gel from six with similar results is 
presented; GAPDH was used as protein loading control. The related densitomeytric 
analysis is shown in Fig. 4SB. C. Immunoblot analysis with specific antibodies against 
atrial natriuretic peptide (ANP), vascular adhesion molecule -1 (VCAM-1), intracellular 
adhesion-molecule- 1 (ICAM-1) and PDGF-B of lung from Prx2-/- mice under normoxia 
(lane 1) and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2.  One 
representative gel from six with similar results is presented; GAPDH was used as protein 
loading control. Right panel. Relative quantification of immunoreactivity of ANP, VCAM-1, 
ICAM-1 and PDGF-B in lung from Prx2-/- mice under normoxia (lane 1) and exposed to 7 
days (7D) hypoxia treated with either vehicle or PEP Prx2. Data are shown as means ±SD 
(n=6); ^ p<0.05 compared to Prx2-/- normoxic mice; ° p<0.05 compared to Prx2-/- treated 
with vehicle. 
Fig. 5. PEP Prx2 administration reduces the hypoxia related abnormal pulmonary 
vascular leakage and prevents the hypoxia induced lung oxidative damage.  
A. BAL protein content and BAL Leukocyte count from under either normoxic condition (N) 
or exposed to 3 days hypoxia treated with either vehicle or penetrating peptide fusion 
protein peroxiredoxin-2 (PEP Prx2). Data are presented as means± SD (n=6; *p<0.05 
compared to WT mice; ^ p<0.05 compared to normoxic mice; °p<0.05 compare to vehicle 
treated mice). B. The carbonylated proteins (1ug) were detected by treating with DNPH 
and blotted with anti-DNP antibody. Lower panel. Quantification of band area was 
performed by densitometry and expressed as % of WT. The data are presented as means 
± SD of at least three independent experiments *p<0.05 compared to WT; ° p<0.05 
compared to vehicle treated mice (n=3). (C) mmunoblot analysis with specific antibodies 
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against phospho-NF-kB (P-NF-kB), NF-kB, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from 
wildtype (WT) and Prx2-/- mice under normoxic condition treated with either vehicle or 
penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2).  One representative gel 
from six with similar results is presented. Densitometric analysis of immunoblots is shown 
in Fig.5SA.  
Fig. 6. In Prx2-/- mice, PEP Prx2 administration reduces hypoxia related 
inflammatory vasculopathy and down-regulates hypoxia induced autophagy. A. 
Immunoblot analysis with specific antibodies against IL-6, endothelin-1 (ET-1), vascular 
cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B) of lung 
from wildtype (WT) and Prx2-/- mice under normoxic condition treated (lane 1-2) or 
exposed to hypoxia (3D) and treated with either vehicle or penetrating peptide fusion 
protein peroxiredoxin-2 (PEP Prx2).  One representative gel from six with similar results is 
presented. Densitometric analysis of immunoblots is shown in Fig. 5SB. B. Immunoblot 
analysis with specific antibodies against LC3I/II, Ulk1, p62, pro-caspase-caspase 3 of lung 
from wildtype (WT) and Prx2-/- mice under normoxic condition or exposed to 3 days (3D) 
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating peptide 
fusion protein peroxiredoxin-2 (PEP Prx2).  One representative gel from six with similar 
results is presented. Densitometric analysis for LC3I/II, Ulk1, p62, pro-caspase-caspase 3 
is shown in Fig. 6S. (C) Diagram of the novel role of Prx2 in pathogenesis of PAH induced 
by hypoxia/reoxygenation stress and the interplay between ROS and autophagy. Hypoxia 
promotes oxidation and increased levels of ROS. Oxidation induced activation of Nrf2, NF-
kB and autophagy to limit oxidation related damage of cellular organelles and proteins. In 
turn p62 is affectd by Nrf2 activation. Up-regulation of Prx2 in response to hypoxia controls 
oxidation induced by hypoxia. The acute phase response factors modulated by Nrf2 and/or 
NF-kB are (i) HO-1 and SOD-1 as cytoprotector; (ii) VCAM-1, ET-1, ANP affecting 
vascular tone and vascular activation; (iii) and PDGF-B, involved in extra-matrix 
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remodeling and deposition. The hypoxia induced results in (i) conversion of LC3I to LC3II; 
(ii) clearance of p62 positive lysosomes combined with the activation of caspase 3 
pathway. PEP Prx2 treatment prevents the redox related activation of Nrf2, NF-kB and 
autophagy in wild-type and Prx2-/- mice exposed to hypoxia, resulting in reduction in 
markers of vascular remodelling, of matrix deposition and abnormalities in pulmonary 
vascular leakage.  ARE: anti-oxidant responsive element; ET-1: endothelin-1; HO-1: 
heme-oxygenase-1; NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells; 
Nrf2: nuclear erythroid factor 2; P: phosphorylate form of indicated transcriptional factor; 
PAH: pulmonary artery hypertension; PDGF-B: platelet derived growth factor-B; PEP Prx2: 
recombinant fusion penetrating protein Prx2; Prx2: peroxiredoxin 2; ROS: radical oxygen 
species; VCAM-1: vascular cell adhesion molecule 1.  
 
 
 
 
 
 
 
 

SUPPLEMENTARY MATERIALS AND METHODS 
 
Drugs and chemicals. NaCl, Na3VO4, PBS phosphate buffer, bicine, β-
mercaptoethanol, sodium dodecyl sulphate (SDS), albumin from bovine 
serum (BSA) was obtained from Sigma/Aldrich (St Louis, MO, USA), protease 
inhibitor cocktail tablets were from Roche (Basel, Switzerland) 40% 
Acrylamide/Bis Solution, 37.5:1 was from BIO-RAD (Hercules, CA, USA), 
Dulbecco’s Phosphate Buffered Saline (DPBS) was from Lonza (Verviers, 
Belgium), Luminata Forte and Luminata Classico Hrp solutions were from 
Merck Millipore (Armstadt, Germany). 
Immunoblot analysis. Gels were transferred to nitrocellulose membranes for 
immuno-blot analysis with specific antibody: anti NFkB-phospho-S536 (93H1) 
(Cell Signaling Technology, Leiden, NL); anti NFkB p65 (C22B4) (Cell 
Signaling Technology, Leiden, NL); anti Nrf2-phospho-S40 (Clone EP1809Y, 
AbCam, Cambridge, UK); anti Nrf2 (AbCam, Cambridge, UK); anti Interleukin-
6 (IL-6) (Santa Cruz Biotechnology, Heidelberg, Germany); anti Heme 
Oxygenase-1 (HO-1) (Santa Cruz Biotechnology, Heidelberg, Germany), anti 
Superoxide Dismutase 1 (SOD-1) (Santa Cruz Biotechnology, Heidelberg, 
Germany); anti Endothelin-1 (ET-1) (Santa Cruz Biotechnology, Heidelberg, 
Germany); anti VCAM-1 (R and D Systems, Minneapolis, MN, USA); anti 
PDGF-B (AbCam, Cambridge, UK); anti Peroxiredoxin 2 (Prx 2, Clone 1E8, 
AbCam, Cambridge, UK); anti Sestrin-2 (Sigma Aldrich, Saint Louis, MO, 
USA); anti Thioredoxin Reductase (Trdx) ( Santa Cruz Biotechnology, 
Heidelberg, Germany); anti ANP (Gene Tex, Irvine, CA, USA); anti ICAM-
1(AbCam, Cambridge, UK); anti LC3A/B (AbCam, Cambridge, UK); anti ULK-
1 (H-240) (Santa Cruz Biotechnology, Heidelberg, Germany); anti APG7 
(Atg7) (ProSci, Poway, CA, USA); anti SQSTM1/P62 (AbCam, Cambridge, 
UK); anti pro Caspase 3 (E83-103) (AbCam, Cambridge, UK). Anti Actin 
(Sigma Aldrich, Saint Louis, MO, USA) and anti-GAPDH (Sigma Aldrich, Saint 
Louis, MO, USA) were used as loading control. Secondary donkey anti-rabbit 
and anti-mouse IgG HRP conjugated were from GE Healthcare Life Sciences 
and secondary donkey anti-goat IgG HRP conjugated was from SCBT. Blots 
were developed using the Immobilon Western Chemiluminescent HRP 
Substrate from Millipore (Billerica, MA, USA) and images were acquired using 
Image Quant Las Mini 4000 Digital Imaging System (GE Healthcare Life 
Sciences). Densitometric analyses were performed using the ImageQuant TL 
software (GE Healthcare Life Sciences) [26, 30]. Oxidized proteins were 
revealed by the Oxyblot Protein Oxidation Detection Kit (EMD Millipore). In 
brief, the soluble protein extracts were derivatized to 2,4-
dinitrophenylhydrazone (DNP) and 1 µg was loaded on 12% SDS-PAGE, 
blotted and incubated with an anti-DNP antibody, followed by an HRP 
conjugated secondary antibody. The bound activity was revealed by ECL (GE 
Healthcare). Oxidized proteins were revealed by the Oxyblot Protein 
Oxidation Detection Kit (EMD Millipore). In brief, the soluble protein extracts 
were derivatized to 2,4-
on 12% SDS-PAGE, blotted and incubated with an anti-DNP antibody, 
followed by an HRP conjugated secondary antibody. The bound activity was 
revealed by ECL (GE Healthcare).  
 
Echocardiographic measurements. Transthoracic echocardiography was 
performed with a Vevo 2100 echocardiograph (Visual Sonics, Toronto, 
Canada) equipped with a 22-55 MHz transducer (MicroScan Transducers, 
MS500D). Mice were anesthetized by isoflurane inhalation (2%), maintained 
by mask ventilation (isoflurane 1%) and placed in a shallow left lateral 
decubitus position, with strict thermoregulation (37+-1°C) to optimize 
physiological conditions and reduce hemodynamic variability. LV diastolic 
function was measured by analyzing the characteristic flow profile of the 
mitral valve Doppler and tissue Doppler flow, which was visualized in apical 
four-chamber view. The E deceleration time (DT) was taken from the 
maximum of the E wave to its baseline. Two-dimensional images of the 
pulmonary infundibulum were obtained from the parasternal short-axis view at 
the level of the aortic valve and pulsed-wave Doppler recording of the 
pulmonary blood flow was obtained. The pulsed-wave Doppler sample was 
positioned at the tip of the pulmonary valve leaflets and aligned to maximize 
laminar flow according to published methods (PMID 20044514). 
Measurements were performed offline by an operator blinded to the condition 
or genotype of the mice. The following variables were measured: systolic 
time-velocity integral of pulmonary flow (TVI, the area under the flow curve), 
Pulmonary acceleration time (PAT), and right ventricle ejection time (ET). All 
measurements were averaged on 3 consecutive cardiac cycles per 
experiment and cardiac function was assessed when heart rate was 400-450 
bpm. 
 
Table 1S. Oligonucleotide primer sequences used for qRT-PCR of analyzed 
mouse genes 
Gene 
symbol 
Forward primer (5’- 3’) Reverse primer (5’- 3’) 
IL-6  5’-GCCAGAGTCCTTCAGAGAGA-3’ 5’-TGGAAATTGGGGTAGGAAGGA-3’ 
   
For Il-1b and IL.10 oligonucleotide primer sequences see Kalish BT, Matte A, 
Andolfo I, Iolascon A, Weinberg O, Ghigo A, Cimino J, Siciliano A, Hirsch E, Federti 
E, Puder M, Brugnara C, De Franceschi L. Dietary ω-3 fatty acids protect against 
vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica. 
2015 Jul;100(7):870-80.  
SUPPLEMENTAL FIGURE LEGENDS 
Fig. 1S. A. Relative quantification of immunoreactivity of phospho-NF-kB (P-
NF-kB), NF-k, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and 
Prx2-/- mice under normoxic condition. Data are shown as means ±SD (n=6). 
*p<0.05 compared to wildtype. B. 10 g of soluble proteins of lung 
homogenate were tested for MDA-protein adducts. Quantification of band 
area was performed by densitometry and expressed as % of WT. The data 
are presented as means ± SD of at least three independent experiments; 
statistically significant differences were determined by Student’s t-test. 
*p<0.05. C. Relative quantification of immunoreactivity of interleukin 6 (IL-6), 
heme-oxygenase 1 (HO-1), superoxide dismutase 1 (SOD-1); IL-6, heme-
oxygenase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 
(VCAM-1), platelet derived growth factor-B (PDGF-B) and peroxiredoxin-1 
(Prx2) of lung from wildtype (WT) and Prx2-/- mice under normoxic condition. 
Data are shown as means ±SD (n=6). *p<0.05 compared to wildtype. D. 
Immunoblot analysis with specific antibodies against superoxide dismutase-1 
(SOD-1)m atrial natriuretic peptide (ANP), vascular cell adhesion molecule-1 
and intracellular adhesion molecule-1 (ICAM-1) of heart from wildtype (WT) 
and Prx2-/- mice under normoxia (lane 1-2) and exposed to hypoxia for 7 days 
(7D) and treated with either vehicle or PEP Prx2.  One representative gel 
from six with similar results is presented. Right panel. Relative quantification 
of immunoreactivity of SOD-1, ANP, VCAM-1 and ICAM-1. Data are shown 
as means ±SD (n=6). *p<0.05 compared to wildtype; ^ p<0.05 compared to 
normoxic mice.  
Fig. 2S. A. Peroxiredoxin-2 (Prx2), Sestrin-2, Thioredoxin- reductase (Trdx) 
expression in lung tissues (normalized to GADPH) from WT and Prx2-/- mice 
under normoxia (N) and exposed to hypoxia/reoxygenation (H/R) stress (H/R) 
for 10 hours (10 h), 3 days (3D), 7 days (7D). *p<0.05 compared to wildtype; 
^p<0.05 compared to normoxic condition.  Each sample (WT; Prx2-/-) is a pool 
from 5 mice. Representative of three independent experiments. B. Relative 
quantification of immunoreactivity of phospho-NF-kB (P-NF-kB), NF-kB, 
phospho-Nrf2 (P-Nrf2) and Nrf2 of lung  from wildtype (WT) and Prx2-/- mice 
under normoxia (N) and exposed to hypoxia/reoxygenation stress (H/R) for 10 
hours (10 h), 3 days (3D), 7 days (7D). Data are shown as means ±SD (n=6). 
*p<0.05 compared to wildtype; ^ p<0.05 compared to normoxic mice. The 
grey area highlights the changes in theP-Nrf2/Nrf2 and P-NF-kB/NF-kB ratio 
in the mouse strains at 3 days H/R stress.  
Fig. 3S. A. Immunoblot analysis with specific antibodies against phospho-
Nrf2 (P-Nrf2), Nrf2 phospho-NF-kB (P-NF-kB) and NF-kB of lung from 
wildtype (WT) and Prx2-/- mice under normoxic condition. One representative 
gel from six with similar results is presented. Right panel. Relative 
quantification of immunoreactivity of phospho-NF-kB (P-NF-kB), NF-k, 
phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2-/- mice 
under normoxic condition treated with either vehicle or penetrating peptide 
fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means ±SD 
(n=6). *p<0.05 compared to wildtype; °p<005 compared to vehicle treated 
mice. B. Immunoblot analysis with specific antibodies against heme-
oxygenase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 
(VCAM-1), under normoxic condition or exposed to 3 days (3D) 
hypoxiatreated with either vehicle or penetrating peptide fusion protein 
peroxiredoxin-2 (PEP Prx2).  One representative gel from six with similar 
results is presented. Right panel.  Relative quantification of immunoreactivity 
of heme-oxygenase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion 
molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B) of lung from 
wildtype (WT) and Prx2-/- mice under normoxic condition treated with either 
vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2).  
Data are shown as means ±SD (n=6). *p<0.05 compared to wildtype; ° p<005 
compared to vehicle treated mice 
Fig. 4S. A. Representative images of mitral inflow pattern recorded by 
Doppler echo imaging in wildtype (WT) and Prx2-/- mice under hypoxia as in 
Fig. 2B and treated with PEP-Prx2.  B. Relative quantification of 
immunoreactivity of atrial natriuretic peptide (ANP), vascular adhesion 
molecule -1 (VCAM-1), intracellular adhesion-molecule- 1 (ICAM-1) and 
superoxide dismutase-1 (SOD-1) of heart from Prx2-/- mice under normoxia 
and exposed to 7 days (7D) hypoxia treated with either vehicle or PEP Prx2. 
Data are presented as means± SD (n=6); ^p<0.05 compared to Prx2-/- 
normoxic mice; ° p<005 compared to vehicle treated mice. C. The 
carbonylated proteins (1ug) were detected by treating with DNPH and blotted 
with anti-DNP antibody. Lower panel. Quantification of band area was 
performed by densitometry and expressed as % of Prx2 under normoxia. The 
data are presented as means ± SD of at least three independent experiments; 
^p<0.05 compared to Prx2-/- normoxic mice; ° p<005 compared to vehicle 
treated mice. (n=3). 
Fig. 5S. A. Relative quantification of immunoreactivity of phospho-NF-kB (P-
NF-kB), NF-k, phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and 
Prx2-/- mice under normoxia or exposed to 3 days hypoxia  and treated with 
either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP 
Prx2). Data are shown as means ±SD (n=6). *p<0.05 compared to wildtype; ^ 
P<0.05  compared to normoxia; °p<005 compared to vehicle treated mice. B. 
Relative quantification of immunoreactivity interleukin 6 (IL-6), endothelin-1 
(ET-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth 
factor (PDGF-B) under normoxic condition or exposed to 3 days (3D) 
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating 
peptide fusion protein peroxiredoxin-2 (PEP Prx2).  Data are shown as means 
±SD (n=6). *p<0.05 compared to wildtype; ^p<0.05 compared to normoxic 
mice; °p<005 compared to vehicle treated mice. C. Immunoblot analysis with 
specific antibodies against heme-oxygenase-1 (HO-1) of lung from wildtype 
(WT) and Prx2-/- mice under normoxic condition or exposed to 3 days (3D) 
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating 
peptide fusion protein peroxiredoxin-2 (PEP Prx2).  One representative gel 
from five with similar results is presented.  
Fig. 6S.  Relative quantification of immunoreactivity of LC3I/II, Ulk1, p62, pro-
caspase-caspase 3 under normoxic condition or exposed to 3 days (3D) 
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating 
peptide fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means 
±SD (n=6). *p<0.05 compared to wildtype; ° p<0.05 compared to vehicle 
treated mice; ^ p<0.05 compared to normoxic mice.Data are shown as means 
±SD (n=6). *p<0.05 compared to wildtype; ^ p<0.05 compared to normoxic 
mice; °p<005 compared to vehicle treated mice.  
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ABSTRACT  
Peroxiredoxin-2 (Prx2), a typical 2-cysteine-(Cys)-peroxiredoxin, is part of cyto-protective 
systems, controlling cellular oxidation. Here, we studied the effects of iron-overload (IO) 
diet on Prx2 knockout mice (Prx2-/-). The absence of Prx2 enhanced toxicity due to IO on 
erythropoiesis. We found that Prx2-/- mice were unable to induce the typical hepcidin 
(Hamp) overexpression in IO due to failure to activate STAT3. In Prx2-/- mice, the loss of 
Hamp response was also observed after single dose oral iron administration. In IO Prx2-/- 
mice, PEP-fusion-recombinant-Prx2 (PEP-Prx2) treatment significantly (i) decreases 
ineffective erythropoiesis and ameliorates anemia;  (ii) increases STAT3-activation in liver; 
(iii) up-regulates Hamp expression; (iv) reduces liver iron-content. We also confirmed the 
beneficial effects of PEP-Prx2 on Hamp expression through STAT3 activation in β-
thalassemic mice. In conclusion, Prx2 limits IO cytotoxicity on erythropoiesis and affects 
STAT3 transcription activity, regulating Hamp expression. Our data collectively support a 
novel role of Prx2 in iron homeostasis.  
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INTRODUCTION 
Prx2 is a typical 2-cysteine (Cys) peroxiredoxin is part of the cyto-protective 
systems involved in the tight control of the levels of reactive oxygen species (ROS) 
generated during cell’s life span or related to cellular stress such as in iron-overload (1-4). 
Since ROS might also function as a second messenger through transient oxidation of 
cysteine residues on signaling targets, it has been proposed that the redox state of 
cysteine residues of Prxs might control the redox state of partner proteins possibly with on-
off switching mechanism of proteins sensitive to redox conditions (5, 6). 
Recently, we reported that Prx2 is a key anti-oxidant system in both stress and 
pathologic erythropoiesis characterized by oxidative damage, such as β-thalassemia (4, 7-
10). The ablation of Prx2 on β-thalassemic mouse genotype (Prx2-/-Hbb3th/+) worsens the 
ineffective erythropoiesis with increased ROS accumulation, amplified cell apoptosis and 
severe extra-medullary erythropoiesis compared to β-thalassemic (Hbb3th/+) mice (9). In 
addition, Prx2-/-Hbb3th/+ mice display higher iron accumulation in the liver compared to 
either Prx2-/- or Hbb3th/+ mice (9). Administration of Prx2 fused to cell-penetrating carrier 
PEP (cell penetrating peptide; PEP Prx2) significantly ameliorated anemia in Hbb3th/+ mice, 
while decreasing the extent of liver and spleen iron overload (9).  
Iron homeostasis is tightly regulated by a complex system converging on the iron-
regulatory hormone hepcidin (Hamp), which interacts with the cellular iron exporter 
ferroportin to control iron acquisition, storage and plasma iron concentrations (11-17). 
Since the liver is the main site for iron accumulation, redox-sensitive transcription factor 
such as STAT3 might be activated in response to iron accumulation and oxidative stress 
(5, 18-21). Recent studies have noted that physiological levels of ROS promote STAT3 
activation and up-regulate Hamp expression, independently of the well-documented role of 
IL-6 signaling (18). Importantly, high ROS levels down-regulate Hamp expression. (20). It 
is of note that STAT3 transcription activity has been recently linked to Prx2 in presence of 
low levels of H2O2 (5).  
In the present study, we explored the effects of iron overload (IO) in a mice 
genetically lacking Prx2. The absence of Prx2 results in severe anemia and is associated 
with the lack of Hamp induction in response to either IO or following the administration of a 
single dose of oral iron through the loss of STAT3 activation in response to IO. Treatment 
with fused recombinant PEP Prx2 restored both STAT3 activation and Hamp expression in 
response to IO. These findings were also confirmed in Hbb3th/+ mice, used as a mouse 
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and immune-blot protocols used for the analysis of sorted erythroblasts are described in 
supplementary materials and methods (29, 30).  
Generation of recombinant-PEP-1 Prx2 fusion protein (PEP Prx2). The fusion protein 
PEP Prx2 was generated as previously reported (9, 31). 
Histological analysis of spleen and liver. Immediately following dissection, spleen and 
liver were formalin-fixed and paraffin-embedded (32). Details are presented in 
supplementary materials and methods.  
Molecular analysis of liver. Protocols used for RNA isolation, cDNA preparation and 
quantitative qRT-PCR have been previously described. (9, 32) Detailed primer sequences 
are available on request and shown in Table 1S. Liver immuno-blot analysis was 
performed as previously described (33, 34). 
 EMSA. Liver nuclear extract was used for non-radioactive electrophoretic mobility shift 
assay. Detailed protocol is described in supplementary material and methods (35).  
Ferroportin-1 quantification. Ferroportin (Fpn1) quantitation was carried out as 
previously reported (25). Detailed protocol is described in supplementary material and 
methods (25).  
Ferritin quantification. Ferritin content was determined by ELISA as previously described 
(36).  
Dectection of oxidized proteins and peroxidation of lipids. Oxidized proteins were 
monitored using Oxyblot Protein Oxidation Detection Kit (EMD Millipore) as previously 
reported (36, 37). The extent of lipid peroxidation was determined by measuring of MDA 
levels. 
Statistical analysis. Data were analyzed using the 2-way analysis of variance (ANOVA) 
for repeated measures between the mice of various mouse groups. A difference with a P 
<0.05 was considered significant.  
 
 
 
 
 
 
 
 
 
 Haematologica HAEMATOL/2017/166488 Version 1
 6
RESULTS 
Prx2 is an important cyto-protective factor in modulating erythropoiesis under 
condition of excess iron  
In iron-overloaded mice, the ablation of Prx2 is associated with early development of a 
more severe anemia compared to wildtype (Fig. 1A).  As shown in Fig. 1A, Prx2-/- mice 
showed a rapid drop in hemoglobin (Hb) levels with associated increase in mean cell 
volume (MCV), red cell distribution width (RDW; Fig. 1SA) and mean cell hemoglobin 
content (MCH wildtype day 0: 14.5±1.2 vs day 60: 17.9±1.1 pg; p<0.05; MCH Prx2-/- day 0: 
13.9±0.4 vs day 60: 18.4±1.9 p<0.05) and a reduction in reticulocyte count compared to 
wildtype mice (Fig. 1A, right panel). These findings are compatible with the appearance of 
a severe anemia in Prx2-/- in conjunction with significant reduction in 
CD44+TER119+FSChigh erythroid cells in both bone marrow and spleen in IO Prx2-/- mice 
compared to standard diet Prx2-/- mice (Fig. 1B, upper panel; Fig. 1SB; 1SC). IO cytotoxic 
effect on Prx2-/- erythroid precursors was also supported by the reduction in the ratio 
between immature/ mature erythroblasts compared to wildtype (Fig. 1B, lower panel).  This 
finding in combination with marked reduction in reticulocyte count in the context of severe 
anemia in IO Prx2-/- mice implies marked ineffective erythropoiesis. Indeed, in both mouse 
strains at 60 days of IO diet, we found a marked increase in the amount of apoptotic 
orthochromatic erythroblasts compared to standard diet groups (Fig. 1SD).  However, the 
extent of apoptosis was more pronounced in IO Prx2-/- mice compared to IO wildtype mice. 
It is notable that wildtype mice showed increased Prx2 expression in erythroblasts in 
response to IO (Fig. 1SE). Erythropoietin expression was significantly increased in both 
mouse strains in response to anemia induced by IO, but we found higher levels in IO Prx2-
/-
 mice than in IO WT animals (Fig. 1SF). The lack of reticulocyte response in the context 
of very high levels of EPO in IO Prx2-/- mice implies inability of erythroblasts to complete 
terminal erythroid differentiation. 
Since erythroferrone (Erfe; Fam132b) has been linked to iron homeostasis and 
erythropoiesis, (11, 12) we evaluated Erfe expression in sorted erythroblasts from both 
mouse strains. We used the CD44-TER119 strategy to isolate and purify erythroid cells (9, 
25, 28). Under standard diet in wildtype mice, we found up-regulation of Erfe gene 
expression in orthochromatic erythroblasts (pop IV) compared to polychromatic 
erythroblasts (pop III) (Fig. 1C). Conversely, we observed up-regulation of Erfe expression 
in Prx2-/- polychromatic erythroblasts (Pop III) and down-regulation of Erfe in Prx2-/- 
orthochromatic erythroblasts (Pop IV) compared to wildtype (Fig. 1C). This altered 
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expression of Erfe might be related to ineffective erythropoiesis in Prx2-/-, which is similar 
to that described in β-thalassemic mice (Hbb3th/+) (9). Our data are in agreement with up-
regulation of Erfe previously reported in polychromatic erythroblasts from Hbb3th/+ mice 
(11). IO promoted down-regulation of Erfe to similar extent in both mouse strains (Fig. 1C) 
and this is associated with almost undetectable soluble levels of Erfe in both IO mouse 
strains (data not shown). Collectively these data suggest that the absence of Prx2 is 
associated with amplified iron cytotoxicity.  
Iron overloaded Prx2-/- mice show down-regulation of hepcidin expression and 
reduced STAT3 activation    
We then evaluated liver iron concentration (LIC), which was similarly increased in both 
mouse strains exposed to IO (data not shown). However, Perl’s staining analysis revealed 
different patterns of iron distribution in cellular components of the liver. In Prx2-/- mice, iron 
accumulated in hepatocytes and Kupffer cells, while, iron-deposits were present only in 
hepatocytes of wildtype liver (Fig. 1D). This may be related to hyper- activation response 
of macrophages lacking Prxs as previously shown in other models (38, 39).  Iron 
distribution pattern in the spleen of Prx2-/- mice was similar to that of the liver (Fig. 2SA). 
Oxyblot analysis and quantification of MDA levels were used to evaluate the degree of 
protein oxidation and lipid peroxidation respectively in the liver. Both oxidative processes 
were significantly increased in IO Prx2-/- compared to wildtype mice (Fig. 2A). The levels of 
ferritin H chain, the expression of which increases in response to IO and oxidative stress 
(36, 37), were higher in Prx2-/- mice than in wildtype mice (Fig. 2SB).  
Expression of Prx2 in liver was significantly increased in IO wildtype compared to animals 
under standard diet, indicating that Prx2 is part of the adaptive liver cellular response to IO 
(Fig. 2B). Indeed, we found increase in other known cyto-protective systems, including 
Nqo1 and HO-1 (Fig. 2B). It is interesting to note that up-regulation of Nqo1 and HO-1 in 
response to IO was higher in Prx2-/- mice than in wildtype, while basal levels were similar 
in the two strains (Fig. 2B). These findings suggest that in the absence of Prx2 there is a 
severe oxidative stress in liver of IO Prx2-/- compared to IO wildtype mice.  
Since Prx2 has been recently linked to STAT3 function and oxidative stress, we then 
evaluated the activity of STAT3, which contributes to the regulation of Hamp expression 
(18, 20). In IO wildtype mice, we found increased activation of STAT3 compared to mice 
on standard diet. However, this activation was absent in IO Prx2-/- mice (Fig. 2C, upper 
panel; Fig. 2SC). This finding was further confirmed by DNA-binding activity of STAT3, 
which was increased in liver from WT IO and markedly reduced in IO Prx2-/- mice (Fig. 2C, 
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lower panel).  No major change in liver IL-6 expression was detectable in either IO mouse 
strains (data not shown, see also Fig. 7SB). As expected we found up-regulation of Hamp 
in IO wildtype mice, while no change in Hamp expression was observed in IO Prx2-/- 
compared to standard diet Prx2-/- mice (Fig. 2D). To better understand the role of Prx2 in 
the signaling pathway involved in Hamp regulation, we evaluated Smad 1/5 activation and 
Id1 expression in IO mice (14). Smad activation and up-regulation of Id1 in response to IO 
was similar in both mouse strains (Fig. 2SD, 3SA). We found reduced staining for Fpn1 in 
C-duodenal from IO WT mice compared to standard diet, while no changes were observed 
in Prx2-/- mice with and without IO (Fig. 3SB). 
Prx2 is required to ensure adequate hepcidin expression in response to acute iron 
stimuli 
In order to better understand the interplay between Prx2 and Hamp in response to iron, we 
administered single dose of oral iron (acute iron, AI). Prx2 liver expression significantly 
increased in WT mice at 24 hours after AI (Fig. 2E, 3SC left panel). STAT3 was activated 
in WT but not in Prx2-/- mice treated with AI (Fig. 2E, 3SC right panel). No change in IL-6 
levels was observed in both mouse strains exposed to AI (data not shown). As expected, 
we found significantly increased Hamp expression in liver from WT mice but not in Prx2-/- 
mice (Fig. 2F). No changes were observed in soluble levels of Erfe in repose to acute iron 
administration in both mouse strains (data not shown). Id1 expression was similar in both 
mouse strains after AI (see Fig. 3SD).  
We then evaluated the effects of low iron (LI) diet on hematologic phenotype and Hamp 
expression in both mouse strains. Mice were studied at 3 and 7 weeks of LI. Hamp 
expression was significantly reduced in both mouse strains at 3 and 7 weeks of LI (Fig. 
4SA for Perls staining; Fig. 4SB). Soluble Erfe levels were significantly increased following 
7 weeks of LI diet in both mouse strains (data not shown). EPO expression was 
significantly increased at 7 weeks of LI in both mouse strains (Fig. 4SC).  
Collectively these data indicate that in Prx2-/- mice Hamp response to iron overload is 
absent and is associated with loss of STAT3 transcription activity.  
Recombinant fused PEP Prx2 ameliorates the IO induced anemia and is associated 
with increased Erfe expression 
Recently, we showed that PEP Prx2 is able to reduce ineffective erythropoiesis, ameliorate 
anemia and decrease liver iron-overload in a mouse model for β-thalassemia (9). To 
determine whether PEP Prx2 also protects erythroid cells against the toxicity of IO, we 
administrated PEP Prx2 to wildtype and Prx2-/- mice under IO diet. PEP Prx2 
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administration was started at the same time as the IO diet. In both IO wildtype and IO 
Prx2-/- mice, PEP Prx2 to a large extent rescued the IO induced hematologic phenotype 
with (i) amelioration of red cell morphology and reduction in hemichromes (Fig. 5SA, 5SB); 
(ii) increased Hb levels and reduced RDW (Fig. 3A upper panel, 5SC); (iii) increased 
reticulocyte count (Fig. 3A, lower panel).  In agreement, we found a significant increase in 
total erythroblasts (CD44+TER119+ FSChigh) in both mouse strains exposed to IO and 
treated with PEP Prx2 (Fig. 3B). We also noted a significant reduction in the amount of IO-
induced apoptotic orthochromatic erythroblasts in both mouse strains treated with PEP 
Prx2 (Fig. 5SD). The decrease in IO induced ineffective erythropoiesis by PEP Prx2 was 
associated with up-regulation of Erfe in both polychromatic and orthochromatic 
erythroblasts from wildtype and polychromatic erythroblasts from Prx2-/- mice compared to 
erythroid precursors from IO treated mice (Fig. 3C).   
PEP Prx2 treatment supports STAT3 activation with up-regulation of Hamp 
expression in response to IO  
PEP Prx2 treated IO mice showed a marked reduction of iron overload in liver (Fig. 3D, 
6SA) and reduced protein oxidant damage (Fig. 6SB). In both PEP Prx2 treated IO mouse 
strains, we found a marked activation of STAT3 compared to vehicle treated mice (Fig. 3D, 
6SC). Hamp expression was significantly increased in both PEP Prx2 treated IO mouse 
strains (Fig. 3E). Smad activation was reduced by PEP Prx2 treatment in both IO mouse 
strains compared to vehicle treated IO mice (Fig. 6SD). No changes in IL-6 expression 
were observed in liver from PEP Prx2 treated IO mice (Fig. 7S). These findings imply PEP 
Prx2 blunts IO-related Smad activation, but promotes STAT3 activation with up-regulation 
of Hamp expression in both mouse strains.   
In β-thalassemic mice, PEP Prx2 treatment up-regulates Hamp expression in liver 
and is associated with STAT3 activation 
We previously reported that PEP Prx2 administration significantly ameliorates β-
thalassemic anemia in conjunction with decreased ineffective erythropoiesis and reduced 
liver iron overload (9). In both PEP Prx2 treated Hbb3th/+ and wildtype mice, we found 
increased Hamp mRNA levels compared to vehicle treated mice (Fig. 4A). STAT3 was 
significantly activated in both PEP Prx2 treated mouse strains compared to vehicle treated 
groups (Fig. 4B). These data collectively suggest that Prx2 modulates STAT3-regulated 
hepatic Hamp expression in both Hbb3th/+ and wildtype mice.    
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DISCUSSION 
 Our study documented for the first time that Prx2 plays a critical role as cyto-
protector against toxic effects of iron overload on erythropoiesis. Absence of Prx2 and 
associated loss of the expected iron-induced increase in Hamp expression in Prx2-/- 
mouse liver in part account for deleterious effects of iron overload. 
In response to IO, Prx2-/-mice displayed reduced STAT3 activation compared to wildtype 
animals. Previous studies have shown that ROS levels significantly influence the activation 
status of STAT3 affecting Hamp expression in response to IO or IL-6 mediated 
inflammatory system (18, 20). Thus, the failure in STAT3 activation in IO Prx2-/- mice 
represents the key event responsible for the lack of Hamp up-regulation in response to IO. 
This conclusion is bolstered by our finding that in contrast to STAT3, Smad activation was 
similar in both IO mouse strains. In addition, the reduced expression of Erfe in erythroid 
precursors as well as of circulating Erfe levels in both mouse strains exposed to IO is in 
agreement with previous reports and indicates that Erfe is not involved in the loss of Hamp 
expression observed in IO Prx2-/- mice. By exploring the effects of acute iron administration 
of Hamp expression in Prx2-/- mice, we documented that the absence of Prx2 affects Hamp 
expression in Prx2-/- mice and is associated with reduced STAT3 activation. Taken 
together these findings imply a robust interplay between iron and Prx2 Hamp pathway.  
The loss of the functional connection between Erfe and Hamp in the absence of Prx2 is 
another novel element in the scenario of iron homeostasis and ineffective erythropoiesis in 
presence of adequate EPO levels. Indeed, the administration of PEP Prx2, which we 
previously reported to ameliorate ineffective erythropoiesis in both Prx2-/- and Hbb3th/+ mice 
(9), significantly ameliorated the IO induced cytotoxic effect on erythropoiesis and was 
associated with up-regulation of Erfe in both mouse strains. This effect was more 
pronounced in wildtype than in Prx2-/- mice, most likely related to the fact that the 
exogenous PEP Prx2 does not fully compensate the absence of Prx2 in Prx2-/- mice.  
Data from the mouse model of β-thalassemia (Hbb3th/+) further support a functional 
connection between Prx2 and STAT3 towards Hamp expression. We took the advantage 
of our previous observation that PEP-Prx2 administration ameliorates the ineffective 
erythropoiesis and iron overload in β-thalassemic mice (9) and showed marked activation 
of STAT3 and up-regulation of liver Hamp expression in PEP Prx2 treated Hbb3th/+ mice, 
supporting a key role of Prx2 in iron homestasis. 
In summary, we propose that Prx2 controls oxidative stress and modulates targets 
sensitive to redox conditions such as STAT3 (Fig. 4C). Thus, Prx2 levels might act as a 
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on-off switch of STAT3 transcription activity, profoundly affecting Hamp expression in 
response to IO (Fig. 4C). The effects of PEP Prx2 on STAT3 activation and Hamp 
expression in either IO mice or β-thalassemic mice further support this working model. The 
amelioration of IO induced ineffective erythopoiesis in PEP Prx2 treated mice supports the 
role of Prx2 as “big brother” in controlling IO induced cytotoxicity and optimizing the 
functional pathway involved in iron homeostasis. These findings suggest a novel 
therapeutic strategy to control clinical consequences of iron overload through modulation 
of Prx2 activity.  
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FIGURES 
Fig. 1. Iron overload (IO) bone marrow and liver cytoxicity is amplified in the 
absence of Prx2. (A) Hemoglobin (Hb), mean cell volume (MCV) and reticulocyte count in 
wildtype (WT; n=12) and Prx2-/- (n=12) mice exposed to iron-overload (IO) diet. No data 
were available on red cell indices and reticulocyte count for Prx2-/- exposed to 90 days IO 
due to the severe anemia (Hb   g/dL). Data are presented as means ±SD; *p< 0.05 
compared to WT mice; °p<0.05 compared to baseline values. (B) Upper panel. 
CD44+/TER119+/FSChigh bone marrow erythroid cells in wildtype (WT; n=6) and Prx2-/- 
(n=6) mice after 90 days of either standard diet or iron-overload (IO) diet. Data are 
presented as means ±SD; *p< 0.05 compared to WT mice; °p<0.05 compared to standard 
diet. Lower Panel. Bar graph showing the ratio between early erythroid precursors (pro- 
basophilic- polychromatic- erythroblasts) and late erythroid precursors (orthochromatic 
erythroblasts) in bone marrow analyzed by flow cytometry from wildtype (WT; n=6) and 
Prx2-/- (n=6) after 90 days of either standard diet or iron-overload (IO) diet. Data are 
presented as means ±SD; *p< 0.05 compared to standard diet. (C) RT-PCR expression of 
erythroferrone (Erfe; Fam132b) on sorted mouse polychromatic (Pop III) and 
orthochromatic (Pop IV) erythroblasts from bone marrow of wildtype and Prx2-/- mice after 
under either standard diet or iron-overload (IO) diet. Experiments were performed in 
triplicate. Error bars represent the standard deviations (mean ± SD); *p<0.05, **p ≤0.001. 
The graphs were created using the Software GraphPad Prism 6. (D) Left panel. 
Macroscopic appearance of liver from wildtype (WT) and Prx2-/- mice exposed to iron-
overload diet (IO). One representative image from the other 6 with similar results is 
presented. Iron staining (Pearl’s Prussian blue) in liver from wildtype (WT) and Prx2-/- mice 
exposed to iron-overload diet (IO). One representative image from the other 6 with similar 
results is presented. In the inset, the arrow indicates macrophages with iron accumulation.  
Right panel. Quantification of iron staining on Pearl’s Prussian blue liver from wildtype 
(WT) and Prx2-/- mice (see Methods). Data are shown as means ±SD (n=10); *P<0.05 
compared to WT (n=6). 
 
Fig.2. Lacking in STAT3 activation and Hamp up-regulation in response to iron-
overload and acute iron administration characterized Prx2-/- mice.  (A) Upper panel. 
Soluble fractions of liver of WT IO and Prx2-/-IO were analyzed on 12% SDS-PAGE and 
subjected to immunoblotting. The carbonylated proteins were detected by treating with 
DNPH and blotted with anti-DNP antibody. Lower panel. 10 μg of soluble proteins of liver 
 Haematologica HAEMATOL/2017/166488 Version 1
 17
homogenate were tested for MDA-protein adducts. Quantification of band area was 
performed by densitometry and expressed as % of WT. The data are presented as means 
± SD of at least three independent experiments; statistically significant differences were 
determined by Student’s t-test. *p<0.05, **p<0.001. (B) Western-blot (Wb) analysis with 
specific antibodies against Peroxiredoxin-2 (Prx2), NAD(P)H dehydrogenase quinone 
(Nqo1) and heme-oxygenase (HO-1) of liver from wildtype (WT) and Prx2-/- mice exposed 
to either standard diet or iron-overload diet (IO). One representative gel from 6 with similar 
results is presented. Densitometric analysis of immunoblots is shown in bar graph (lower 
panel); Data are presented as means ±SD; *p<0.05 compared to WT, °p<0.05 standard 
diet. (C) Upper panel. Western-blot (Wb) analysis with specific antibodies against 
phospho-STAT3 (P-STAT3) and STAT3 of liver from wildtype (WT) and Prx2-/- mice 
exposed to either standard diet or iron-overload diet (IO). One representative gel from 6 
with similar results is presented (see Fig. 2SC for densitometric analysis). Lower panel. 
Non-radioactive EMSA analysis of nuclear protein extracted from pooled liver of four to six 
mice under standard (St) diet or iron overload (IO). Arrows indicates STA3 homodimer. (D) 
RT-PCR expression of hepcidin (Hamp) on liver from wildtype and Prx2-/- mice exposed to 
either standard diet or iron-overload diet (IO). Experiments were performed in triplicate. 
Error bars represent the standard deviations (mean ± SD); *p<0.05 compared to WT, 
°p<0.05 standard diet. The graphs were created using the Software GraphPad Prism 6. 
(E) Western-blot (Wb) analysis with specific antibodies against peroxiredoxin-2 (Prx2), 
phospho-Nrf2 (P-Nrf2), Nrf2, phospho-STAT3 (P-STAT3) and STAT3 of liver from wildtype 
(WT) and Prx2-/- mice exposed to either vehicle or acute single iron dose (AI). One 
representative gel from 6 with similar results is presented (see Fig. 3SC for densitometric 
analysis). (F) RT-PCR expression of hepcidin (Hamp) on liver from wildtype and Prx2-/- 
mice exposed to either vehicle or acute single iron dose (AI). Experiments were performed 
in triplicate. Error bars represent the standard deviations (mean ± SD); °p<0.05 vehicle 
mouse groups. The graphs were created using the Software GraphPad Prism 6.  
 
Fig.3. Recombinant fusion PEP Prx2 protein ameliorates IO induced anemia and 
ineffective erythropoiesis with activation of STAT3 and up-regulation of hepcidin. 
(A) Hemoglobin (Hb), mean cell volume (MCV) and reticulocyte count in wildtype (WT; 
n=8) and Prx2-/- (n=8) mice exposed to either iron-overload (IO) diet or IO plus PEP Prx2 
treatment. No data were available on red cell indices and reticulocyte count for Prx2-/- 
exposed to IO due to the severe anemia (Hb   g/dL). Data are presented as means ±SD; 
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*p< 0.05 compared to WT mice; §p<0.05 compared to IO vehicle treated mice. (B) Bar 
graph showing CD44+/TER119+/FSChigh bone marrow cells in wildtype (WT; n=8) and 
Prx2-/-  (n=8) mice exposed to either iron-overload (IO) diet or IO plus PEP Prx2 treatment. 
Data are presented as means ±SD; *p< 0.05 compared to WT mice; §p<0.05 compared to 
IO vehicle treated mice. (C) RT-PCR expression of erythroferrone (Erfe; Fam132b) on 
sorted mouse polychromatic (Pop III) and orthochromatic (Pop IV) erythroblasts from bone 
marrow of wildtype and Prx2-/- mice under either iron-overload (IO) diet without or with PEP 
Prx2 treatment. Experiments were performed in triplicate. Error bars represent the 
standard deviations (mean ± SD); *p< 0.05 compared to WT mice, §p<0.05 compared to 
IO vehicle treated mice; ^p<0.05 Pop III vs Pop IV (n=6 from each mouse strains). The 
graphs were created using the Software GraphPad Prism 6. (D) Iron staining (Pearl’s 
Prussian blue) in liver from wildtype (WT) and Prx2-/- mice exposed to iron-overload diet 
(IO) and treated with either vehicle or PEP Prx2. One representative image from the other 
6 with similar results is presented (related iron score is shown in Fig. 6SA)  (E) Western-
blot (Wb) analysis with specific antibodies against phospho-STAT3 (P-STAT3) and STAT3 
of liver from wildtype (WT) and Prx2-/- mice exposed to iron-overload diet (IO) with or 
without PEP Prx2 treatment. One representative gel from eight with similar results is 
presented. Densitometric analysis of immunoblots are shown in bar graph in Fig. 6SC. (F) 
RT-PCR expression of hepcidin (Hamp) on liver from wildtype and Prx2-/- mice exposed to 
either standard diet or iron-overload diet (IO) with or without PEP Prx2. Experiments were 
performed in triplicate. Error bars represent the standard deviations (mean ± SD; n=6); 
p<0.05 compared to WT, °p<0.05 standard diet, § p<0.05 IO vehicle treated mice. The 
graphs were created using the Software GraphPad Prism 6. 
 
Fig.4 Recombinant fusion PEP Prx2 protein is associated with STAT3 activation and 
up-regulation of hepcidin in a mouse model for β-thalassemia (Hbb3th/+). (A) RT-PCR 
expression of hepcidin (Hamp) on liver from wildtype and Hbb3th/+ mice exposed to either 
vehicle or PEP-Prx2 treatment. Experiments were performed in triplicate. Error bars 
represent the standard deviations (mean ± SD; n=6); *p<0.05 compared to WT, § p<0.05 
vehicle treated mice. The graphs were created using the Software GraphPad Prism 6. (B) 
Western-blot (Wb) analysis with specific antibodies against phospho-STAT3 (P-STAT3) 
and STAT3 of liver from wildtype (WT) and Hbb3th/+ mice with or without PEP Prx2 
treatment. One representative gel from 6 with similar results is presented. Densitometric 
analysis of immunoblots is shown in bar graph (right panel); Data are presented as means 
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±SD (n=6 from each strains); *p<0.05 compared to WT, § p<0.05 IO vehicle treated mice. 
(C) Schematic diagram of the novel role of Prx2 in iron homeostasis facing iron overload 
induced ineffective erythropoiesis. Prx2 controls oxidative stress, modulating targets 
sensitive to redox conditions STAT3. Prx2 levels might act as a switch of on-off STAT3 
transcription activity, profoundly affecting Hamp expression in response to IO. ROS: 
radical oxygen species; Prx2: peroxiredoxin 2; Hamp: hepcidin; P: phosphorylate form of 
indicated transcriptional factor; STAT3: signal transducer and activator of transcription 3.  
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Red Cell Biology & Its Disorders
Introduction
Sickle cell disease (SCD) is a worldwide hereditary red cell
disorder caused by a point mutation in the β-globin gene
resulting in the synthesis of pathological hemoglobin S (HbS),
and abnormal HbS polymerization in hypoxic conditions.1
The two main clinical manifestations of SCD are chronic
hemolytic anemia and acute vaso-occlusive crises (VOC),
which are the principal causes of hospitalization of SCD
patients. Recent studies have underscored the central role of
sickle vasculopathy in the generation of sickle cell-related
acute events and chronic organ complications.2-4 The patho-
physiology of these complications is based on intravascular
sickling in capillaries and small vessels leading to vaso-occlu-
sion, impaired blood flow, vascular inflammation, and throm-
bosis with ischemic cell damage.2-4 Studies in various models
of vasculopathy, including those with ischemia and inflam-
mation, have shown protective effects of ω-3 polyunsaturat-
ed fatty acid (PUFA) supplementation.5 This is supported by
several mechanisms: (i) favorable changes in cell membrane
lipid composition;6 (ii) modulation of soluble and cellular
inflammatory responses;7 (iii) modulation of the coagulation
cascade,8 and (iv) production of nitric oxide.9
The fatty acid profile of the red cell membrane from SCD
patients is intrinsically different from that of healthy controls,
with a relative increase in the ratio of ω-6 to ω-3 PUFA.10,11
Sickle erythrocytes have increased ω-6-derived arachidonic
acid (20:4n6) and decreased eicosapentaenoic acid (20:5n3)
and docosahexaenoic acid (22:6n3).10,11 Recently, human stud-
ies have demonstrated that supplementation of SCD subjects
with fish oil containing ω-3 fatty acids reduces VOC, pain
episodes, and blood transfusions.12-14 To date, however, there
are insufficient clinical and molecular data to support routine
dietary supplementation with fish oil for SCD patients.
In the present study, we studied the effects of an ω-3 diet
(fish oil diet, FD) on the vasculopathy of a humanized mouse
model for SCD. The evaluation of the impact of FD supple-
mentation on SCD is relevant since the typical Western diet
has a 15:1 ratio of ω-6 to ω-3 PUFA.15
We found that in SCD mice, the FD modified sickle red cell
membrane lipid composition and was associated with a
reduction in vascular activation and an improvement of car-
diovascular dysfunction. In a model of acute VOC induced by
exposure to hypoxia-reoxygenation (H/R) stress, we showed
that  FD decreases vascular activation, modulates the inflam-
matory response, and reduces sickle cell-related organ dam-
age. Thus, our findings shed new light on the significance of
PUFA in SCD and VOC and support a therapeutic role of ω-3
PUFA supplementation in SCD.
Methods 
Mice and study design 
Experiments were performed on 4- to 6-week old healthy control
(Hbatm1(HBA)Tow Hbbtm3(HBG1,HBB)Tow) and SCD (Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB*)Tow)
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The anemia of sickle cell disease is associated with a severe inflammatory vasculopathy and endothelial dysfunc-
tion, which leads to painful and life-threatening clinical complications. Growing evidence supports the anti-inflam-
matory properties of ω-3 fatty acids in clinical models of endothelial dysfunction. Promising but limited studies
show potential therapeutic effects of ω-3 fatty acid supplementation in sickle cell disease. Here, we treated human-
ized healthy and sickle cell mice for 6 weeks with ω-3 fatty acid diet (fish-oil diet). We found that a ω-3 fatty acid
diet: (i) normalizes red cell membrane ω-6/ ω-3 ratio; (ii) reduces neutrophil count; (iii) decreases endothelial acti-
vation by targeting endothelin-1 and (iv) improves left ventricular outflow tract dimensions. In a hypoxia-reoxy-
genation model of acute vaso-occlusive crisis, a ω-3 fatty acid diet reduced systemic and local inflammation and
protected against sickle cell-related end-organ injury. Using isolated aortas from sickle cell mice exposed to hypox-
ia-reoxygenation, we demonstrated a direct impact of a ω-3 fatty acid diet on vascular activation, inflammation,
and anti-oxidant systems. Our data provide the rationale for ω-3 dietary supplementation as a therapeutic inter-
vention to reduce vascular dysfunction in sickle cell disease. 
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ABSTRACT
mice.16,17 The animal protocol was approved by the Animal Care
and Use Committee of the University of Verona (CIRSAL). Two-
month old animals were fed for 6 weeks with either the standard
AIN-93M purified rodent diet (soy-diet with n6/n3 ratio of 8:1 -
Dyets Inc., Bethlehem, PA, USA), containing 140 g/kg casein, 1.8
g/kg L-cystine, 100 g/kg sucrose, 465.9 g/kg cornstarch, 155 g/kg
dextrose, 40 g/kg soybean oil, 0.8 mg/kg t-butylhydroquinone, 50
g/kg cellulose, 35 g/kg mineral mix, 10 g/kg vitamin mix, and 2.5
g/kg choline bitartrate18 or the ω-3 FD, an AIN-93M-based purified
rodent diet in which all of the calories provided by fat (10%) are
replaced by 7.9% from HCO and 2.1% from ω-3 oil (Dyets Inc.,
Bethlehem, PA, USA). At the end of the 6 weeks of FD supplemen-
tation, animals were anesthetized with isofluorane, and whole
blood was collected from each mouse via retro-orbital venipunc-
ture by heparinized microcapillaries. Mice were euthanized and
organs removed immediately. The organs were divided into two
and either frozen immediately in liquid nitrogen or fixed in 10%
formalin and embedded in paraffin for histology. Whenever indi-
cated, 6-week old mice were exposed to hypoxia (8% oxygen for
10 h) followed by 3 h of reoxygenation (21% oxygen) (H/R stress)
to mimic an acute VOC, as previously described.19
Hematologic parameters and red cell indices 
Hematologic parameters and red cell indices were measured as
previously described.19-21 Details are reported in the Online
Supplementary Materials and Methods.  
Red cell fatty acid composition 
Red cell membrane total lipids were extracted as previously
reported22 and determined by gas liquid chromatography using a
Hewlett Packard 6890 equipped with a flame ionization detector.
Peaks were identified by comparison of retention times with
external fatty acid methyl ester standard mixtures from NuCheck
Prep (Elysian, MN, USA). The fatty acid profiles were expressed as
percentage of the total fatty acid (weight percent). 
Blood pressure and echocardiographic measurements 
Heart rate, systolic, diastolic, and mean blood pressures were
measured in conscious mice with a non-invasive computerized tail
cuff system (CODA, Kent Scientific Corp) as previously reported.16
Transthoracic echocardiography was performed with a Vevo 2100
echocardiograph (Visual Sonics, Toronto, Canada) equipped with
a 22-55 MHz transducer (MicroScan Transducers, MS500D) as
previously described.16 Details are reported in the Online
Supplementary Materials and Methods. 
Histological analysis
Multiple (at least five) three-micron whole mount sections were
obtained for each paraffin-embedded liver and stained with hema-
toxylin & eosin, Masson trichome, and May-Grünwald-Giemsa.
The lung and liver pathology were analyzed and the liver patho-
logical score, inflammatory cell infiltrate and presence of thrombi
were determined by blinded pathologists as previously
described.19,23 Details on the histological analysis are provided in
the Online Supplementary Materials and Methods.
Tissue molecular analysis 
Total RNA was extracted from mouse tissues using Trizol
reagent (Life Technologies). cDNA was synthesized from total
RNA (2 μg) using Super Script II First Strand kits (Life
Technologies). Quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) was performed using the SYBR-green
method as previously reported.24 Primers used are reported in
Online Supplementary Table S1. For the immunoblot analysis,
frozen lungs, livers, and aortas from each studied group were
homogenized and lysed with iced lysis buffer (LB containing: 150
mM NaCl, 25 mM bicine, 0.1% SDS, Triton 2%, EDTA 1 mM,
protease inhibitor cocktail tablets (Roche), 1 mM Na3VO4 final
concentration) then centrifuged at 12,000 for 10 min at 4°C g.25
Proteins were quantified and analyzed by one-dimensional sodi-
um dodecylsulfate polyacrylamide gel electrophoresis. Gels were
transferred to nitrocellulose membranes for immunoblot analysis
with specific antibodies. Detailed information on the antibodies
used is provided in theOnline Supplementary Materials and Methods. 
Bronchoalveolar lavage measurements 
Bronchoalveolar lavage (BAL) fluids were collected and cellular
contents were recovered by centrifugation and counted by micro-
cytometry as previously reported.19,26 The percentage of neu-
trophils was determined on cytospin centrifugation. The remain-
ing BAL samples were centrifuged at 1,500 x g for 10 min at 4°C.
The supernatant fluids were used for determination of total pro-
tein content.19,26
Statistical analysis 
The two-way ANOVA algorithm for repeated measures com-
bined with Bonferroni correction was used for data analysis.
Differences with P<0.005 were considered statistically significant. 
Results
ω-3 polyunsaturated fatty acids modify red cell 
membrane composition and reduce neutrophil count
in mice with sickle cell disease
We analyzed the lipid composition of red cell mem-
branes from healthy (AA) and sickle cell (SS) mice fed with
isocaloric diets containing either soy (SD) or fish-oil (FD)
for 6 weeks. As shown in Figure 1A and Online
Supplementary Table S2, red cell membrane ω-6 content
was higher in SS-SD mice than in AA-SD mice, similar to
that observed in human SCD patients.13 FD supplementa-
tion markedly increased ω-3 membrane content in both
AA-FD and SS-FD mice, resulting in a dramatically lower
ω-6/ω-3 ratio compared to that in both mouse strains fed
SD (Figure 1A, Online Supplementary Table S2). In addition,
in SS mice, FD resulted in significantly increased mean cor-
puscular volume and decreased mean cell hemoglobin
concentration compared to control mice fed with SD,
without significant changes in hemoglobin levels. No dif-
ferences in hematologic parameters or red cell indices
were evident in AA mice based on which of the two
dietary interventions they received (Table 1). Interestingly,
SS-SD mice showed increased neutrophil counts com-
pared to AA-SD mice, as reported in other mouse models
of SCD, a likely indication of elevated chronic systemic
inflammation.27 As shown in Table 1, FD reduced the neu-
trophil count by 30.4±7.2% (n=6) and 64.6±15.1% (n=6)
in AA mice and SS mice, respectively, compared to the
counts in SD groups. Since inflammation plays an impor-
tant role in the pathogenesis of vasculopathy in SCD,4 we
evaluated the impact of FD on cardiovascular function in
SCD mice.
ω-3 polyunsaturated fatty acids beneficially affect
the cardiovascular system and endothelial activation 
in sickle cell mice
Vascular system. As shown in Figure 1B, FD treatment of
SS mice resulted in a significantly lower diastolic blood
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pressure compared to that in either SS mice or AA mice
fed SD. In order to understand the effects of FD on the
vascular system in SCD better, we isolated aortas from AA
and SS mice and evaluated the expression of endothelin-1
(ET-1) as a key vasoactive and pro-inflammatory
cytokine,28 vascular adhesion molecule 1 (VCAM-1) as a
marker of vascular endothelial activation,29 and heme-oxy-
genase-1 (HO-1) as an efficient anti-oxidant system inter-
facing heme overload and vascular inflammation in
SCD.16,30 As expected, ET-1, VCAM-1 and HO-1 expres-
sion was increased in aortas from SS mice compared to
that in AA mice fed the SD (Figure 1C, lanes 1 and 3). In
SS mice, FD significantly reduced the expression of all
three markers compared to their levels in SS control mice,
reaching values similar to those observed in AA mice
(Figure 1C, see also Online Supplementary Figure S1A for
densitometric analysis). 
Cardiac system. Echocardiographic measurements were
carried out in both mouse strains fed either SD or FD diet.
In SS-SD mice, we observed left ventricular hypertrophy, as
measured by the ratio of heart weight to body weight, as
well as a significant increase in left ventricular outflow tract
diameter compared to that in AA-SD mice (Figure 1D). FD
significantly reduced left ventricular outflow tract diameter
in SS mice, without causing changes in the heart weight to
body weight ratio (Figure 1D). No major differences were
present in AA mice. Heart VCAM-1 and HO-1 expression
was significantly higher in SS mice than in AA mice fed the
SD (Figure 1D, lower panel). FD supplementation signifi-
cantly reduced VCAM-1 and HO-1 in SS mice compared to
levels in both SS and AA-SD groups (Figure 1D lower panel,
Online Supplementary Figure S1B for densitometric analysis).
No major differences were observed in ET-1 expression in
either AA or SS mouse strains (Figure 1D, see also Online
Supplementary Figure S1B for densitometric analysis).
These data suggest that in SS mice, FD reduces bio-
chemical markers of vascular/oxidant damage and
decreases evidence of ventricular loading.   
ω-3 polyunsaturated fatty acids reduce pulmonary 
vascular permeability and endothelin-1 expression
in mice with sickle cell disease
Abnormal vascular activation plays an important role in
pulmonary complications of SCD.4,19 ω-3 PUFA has previ-
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Figure 1. FD modified red cell membrane fatty acid composition and beneficially affects cardiovascular system in sickle cell mice. (A) Total ω-
6 fatty acids (n-6) and ω-3 fatty acid/ ω-6 fatty acid ratio (n3/n6 ratio) red cell membrane content as determined by mass spectroscopy in AA
and SS mice under a soy-diet (SD) or fish-oil diet (FD). (B) Measurements of diastolic and systolic blood pressure (upper panel) in AA and SS
mice under a SD or FD. (C) Immunoblot analysis with specific antibodies against endothelin-1 (ET-1), vascular adhesion molecule-1 (VCAM-1)
and heme oxygenase-1 (HO-1) of isolated aortas from AA and SS mice under a SD or FD. One representative gel from six with similar results
is presented. Densitometric analysis of anti- ET-1, VCAM-1 and HO-1 immunoblots is shown in Online Supplementary Figure S1A. (D) Upper
panel. Left ventricular outflow tract (LVOT) diameter and left ventricular hypertrophy expressed as heart weight/body weight (HW/BW61) in AA
and SS mice under a SD or FD. Lower panel. Immunoblot analysis with specific antibodies against ET-1, VCAM-1, and HO-1 of hearts from AA
and SS mice under a SD or FD. One representative gel from six with similar results is presented. Densitometric analysis of immunoblots is
shown in Online Supplementary Figure S1B. 
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ously been shown to be protective in several models of
lung injury.31,32 We evaluated pulmonary vascular leakage
by measuring protein content and leukocyte counts in
BAL fluid from AA and SS mice. As shown in Figure 2A,
SS mice fed the SD had higher BAL protein and leukocyte
levels compared to healthy mice, indicating accumulation
of proteins and inflammatory cells in the alveolar space.
FD significantly reduced both the leukocyte and protein
content in the BAL fluid of the SS mice, suggesting an
amelioration of vascular permeability compared to that in
animals fed the SD (Figure 2A). 
Since ET-1 plays a key role in clearance of alveolar fluid,
local inflammatory response33 and in SCD vasculopa-
thy,28,34 we evaluated the expression of ET-1 in lungs from
SS and AA mice. Pulmonary ET-1 expression at both
molecular and protein levels was significantly increased in
SS-SD mice compared to that in AA-SD (Figure 2B, Online
Supplementary Figure S2A for densitometric analysis). FD
significantly reduced lung ET-1 expression in SS mice
(Figure 2B, Online Supplementary Figures S2A and S3), in
agreement with the observed improvement of pulmonary
vascular leakage (Figure 2A). VCAM-1 levels were similar
in both AA and SS mice, without modulation by ω-3 PUFA
supplementation (Figure 2B, Online Supplementary Figure
S2A). The increased pulmonary inflammatory state was
associated with higher expression of HO-1 in SS mice
than in AA mice, without significant changes in FD-treat-
ed groups (Figure 2B, Online Supplementary Figure S2B).
These data suggest that ω-3 PUFA supplementation signif-
icantly reduces lung ET-1 expression, thereby resolving
Figure 2. FD ameliorates vascular dysfunction in lung and liver from SS mice. (A) Left panel. Bronchoalveolar (BAL) fluid protein content from
AA and SS mice under a soy-diet (SD) or fish-oil diet (FD). Right panel. BAL fluid leukocyte content from AA and SS mice under a SD or FD. (B)
Immunoblot analysis with specific antibodies against endothelin-1 (ET-1); vascular adhesion molecule-1 (VCAM-1) and heme-oxygenase-1 (HO-
1) of lungs from AA and SS mice under a SD or FD. One representative gel from six with similar results is presented. Densitometric analysis
of ET-1, VCAM-1 and HO-1 immunoblots is shown in Online Supplementary Figure S2A. (C) Immunoblot analysis with specific antibodies
against ET-1, VCAM-1, and HO-1 of livers from AA and SS mice under a SD or FD. One representative gel from six with similar results is pre-
sented. Densitometric analysis of ET-1, VCAM-1 and HO-1 immunoblots is shown in Online Supplementary Figure S2B. 
A
B C
Table 1. Hematologic parameters in wild-type (AA) and sickle cell mice (SS)
treated with ω−3 fatty acid supplementation.
AA-SD AA-FD SS-SD SS-FD
(n=12) (n=12) (n=12) (n=14)
Hematocrit (%) 46.6±1.5 47.3±0.7 37.3±3.3° 38.2±1.7
Hemoglobin (g/dL) 13.2±0.2 13.6±0.3 8.3±0.3° 8.7±0.1
MCV (fL) 38.4±0.4 38.6±0.4 51.4±1.5° 55.1±2.33*
MCH (g/dL) 12.3±0.3 12.2±0.5 12.2±0.2 12.2±0.6
CHCM (g/dL) 24.8±0.2 24.1±0.3 25.8±0.2° 23.9±0.2*
HDW (g/dL) 2.87.±0.05 3.01±0.02 4.98±0.09° 4.46±0.1
Reticulocytes (%) 8.67±1.0 9.0±0.7 42.1±12° 40±8.69
Neutrophils (cells/ μL) 961±229 682±120* 6241±1421° 1520±371*
AA: HbA homozygous control mice or wild-type mice; SS: HbS homozygous mice or sickle cell
mice; SD: soy-diet; FD: fish-oil diet;  MCV: mean corpuscular volume; MCH: mean corpuscular
hemoglobin; CHCM:  cell hemoglobin concentration; HDW: heterogeneity of red cell distribution;
*P<0.002 compared to untreated mice; °P< 0.005 compared to AA mice.
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pulmonary vascular permeability and local inflammation
in SCD mice. 
ω-3 polyunsaturated fatty acids modulate hepatic
inflammation and endothelin-1 expression 
in mice with sickle cell disease
Studies in models of liver injury have shown an impor-
tant role of ET-1 on hepatic microvasculature, specifically
related to local ischemic/reperfusion injury and inflamma-
tory response.35,36 Although the liver is not a target organ
for SCD, we have previously demonstrated that its func-
tional anatomy, its high metabolic rate and the fine regu-
lation of its microcirculation make the liver an interesting
window-organ to explore the pathogenesis of SCD vascu-
lopathy and the effects of new therapeutic tools.23 Here,
we found increased inflammatory cell infiltrates in the
liver portal space of SS mice compared to AA mice fed SD
(data not shown). This was associated with increased
expression of ET-1 at both the molecular and protein levels
in livers from SS mice (Figure 2C, see also Online
Supplementary Figure S2B for densitometric analysis and
Online Supplementary Figure S3 for molecular analysis), sug-
gesting a role of ET-1 as both a pro-inflammatory and a
potent vasoconstrictor cytokine in the portal vascular sys-
tem. The levels of VCAM-1 were significantly higher in
livers from SS mice than AA mice, which argues for the
presence of abnormal vascular activation and local inflam-
mation.37 This is in agreement with the increased expres-
sion of HO-1 as a vaso-protective anti-oxidant.16,38 FD sig-
nificantly reduced hepatic expression of ET-1 and HO-1 in
SS mice compared to SS-SD mice, but it did not affect
expression of VCAM-1 in the liver (Figure 2C, Online
Supplementary Figure S2B). 
Hypoxia/reoxygenation stress mimics acute sickle 
cell-related lung and liver damage
To evaluate the impact of FD on acute sickle cell-related
events, we developed a model of acute VOC based on the
exposure of mice to H/R stress.19,23,28 The H/R conditions
were chosen based on previous models of acute VOC
with related tissue injury and preliminary experiments to
identify the time course of H/R that would recapitulate
sickle cell acute organ damage in the present mouse model
of SCD.19,23,28 We selected an experimental protocol of H/R
in which AA and SS mice were exposed to hypoxia (8%
oxygen) for 10 h followed by 3 h of re-oxygenation (21%
oxygen, room air).19,23,28 In SS mice, H/R induced signifi-
cant reductions in hematocrit and hemoglobin and a
marked increase in hemoglobin distribution width, an
index of the amount of dense red cells39 (Figure 3A,B). In
H/R mice fed the SD we observed a significant increase in
neutrophil count in both AA (SD: 257±23.2%; n=6) and SS
mice (176.8±12%; n=6) compared to counts in normoxic
mice, indicating a sustained systemic inflammatory
response to H/R stress (Figure 3C). No major changes
were observed in reticulocyte count comparing SS mice
subjected to H/R stress or normoxic conditions (data not
shown).
Histological analysis revealed that H/R stress induced a
severe sickle cell-related tissue injury in both the lungs and
livers of SS mice (Table 2; Figures 4 and 5). In the lung, H/R
induced inflammatory cell infiltration, as well as bronchial
mucus secretion and thrombi in 80% of the SS mice (Table
2). In AA mice, H/R induced modest inflammatory cell
infiltration with mucus production, but without thrombi
formation (Table 2). Livers from SS mice exposed to H/R
demonstrated severe hepatic injury characterized by the
loss of hepatic architecture, coagulative necrosis, inflam-
matory cell infiltrates and thrombi (Table 2). Livers from
AA mice exposed to H/R demonstrated a modest inflam-
matory cell infiltrate with mild liver damage (Table 2).
ω-3 polyunsaturated fatty acids prevent hypoxia/
reoxygenation-induced formation of dense 
red cells and neutrophilic response
In SS mice, FD: (i) significantly mitigated the H/R-
induced reductions in hematocrit and hemoglobin Hb lev-
els; and (ii) significantly reduced the fraction of H/R-gen-
erated dense red cells, as supported by the decrease in high
distribution width of red cells in these animals compared
with SS mice (Figure 3A,B). In addition, we observed a sig-
nificant reduction in the H/R-induced increased neutrophil
count in both AA-FD (41.9±3.7%; n=6) and SS-FD
(46.6%±23%; n=6) mice compared to the SD groups of
mice (Figure 3C). These findings suggest that ω-3 PUFA
supplementation causes a shift towards an anti-inflamma-
tory phenotype in SS mice during acute VOC.
Hypoxia/reoxygenation-induced sickle cell lung injury
is attenuated by ω-3 polyunsaturated fatty acids 
via the endothelin-1 pathway
The lungs of SS-FD mice exposed to H/R stress showed
reduced inflammatory cell infiltrates (Figure 4B, Table 2),
no mucus filling the bronchi, and fewer thrombotic events
(Figure 4D, Table 2) compared to those of SS-SD mice
(Table 2). Both the protein content and leukocyte counts
of BAL fluid were significantly reduced in SS-FD mice
compared to SS-SD animals (Figure 4E). A reduction in
BAL fluid protein content was also observed in AA-FD
mice exposed to H/R stress (Figure 4E). These findings
indicate a protective role of ω-3 PUFA against the H/R-
induced pulmonary vascular permeability and local
inflammatory cellular response, suggesting a possible
modulation of the H/R-induced ET-1 pathway.28
In SS mice, FD promoted a significant reduction in H/R-
induced ET-1 molecular and protein expression compared
to levels in SS-SD mice (Figure 4F, see also Online
Supplementary Figure S4A,B for densitometric analysis),
which was paralleled by a decrease in endothelin-1B
receptor (ETBR) expression (Online Supplementary Figure
S5A). The ability of FD to blunt the cytokine storm in H/R
stress was also supported by significant reductions in
interleukin-1β and interleukin-10 expression in the lungs
of SS-FD mice compared to SS-SD ones (Online
Supplementary Figure S5B). VCAM-1 expression was
increased in H/R SS mice compared with AA mice, with
no significant differences between FD- and SD-fed SS
mice (Figure 4F, see also Online Supplementary Figure S4B
for densitometric analysis). The absence of effects of FD
on H/R-induced VCAM-1 lung expression in SS mice is
not surprising given that H/R stress promotes a redistribu-
tion of extracellular VCAM-1 towards the alveolar com-
partment, as shown in asthma models.40 This is also sup-
ported by the significant down-regulation of lung VCAM-
1 gene expression in SS-FD and AA-FD mice compared to
SD groups (Online Supplementary Figure S4A). Thus,
VCAM-1 lung expression reflects only one of the function-
al components of VCAM-1 involved in H/R lung injury.
H/R induced a significant up-regulation of HO-1 in SS
mice compared to AA mice, which was prevented in SS-
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FD mice (Figure 4F, Online Supplementary Figure S4B).
These data suggest that FD efficiently protects SS mice
from acute H/R lung injury through the reduction of ET-1
expression and the modulation of the inflammatory
response, as supported by the reduction in inflammatory
cell infiltrates, BAL fluid leukocyte content, and the
decreased expression of HO-1.
ω-3 polyunsaturated fatty acids blunt
the hypoxia/reoxygenation-induced inflammatory
response and decrease vascular activation in the 
livers of sickle cell mice 
The histological analysis of livers from SCD mice
exposed to H/R stress showed that FD markedly reduced
inflammatory cellular infiltrates and thrombi formation
compared to the SD (Figure 5B,D; Table 2). This was in
agreement with a reduced pathologic severity score in
H/R-exposed SS-FD mice compared with SS-SD mice
(Table 2). Serum levels of alananine and aspartate transam-
inases were significantly lower in both AA-FD and SS-FD
mice than in the groups fed the SD (Online Supplementary
Table S3). No significant changes in liver ET-1 expression
were observed in SS-SD mice compared to SS-FD mice
(Figure 5E). We found a marked increase in VCAM-1
expression in SS mice, compared to AA mice, in response
to H/R stress (Figure 5E, see also Online Supplementary
Figure S6A for densitometric analysis). FD reduced the
H/R-related VCAM-1 up-regulation compared to that in
SS-SD mice (Figure 5). HO-1 expression in response to
H/R was higher in livers of SS mice than in AA mice, but
it was unaffected by ω-3 PUFA supplementation (SS-FD
and AA-FD; Figure 5). Interestingly, HO-1 mRNA levels
were down-regulated in SS-FD mice compared to SS-SD
mice (Online Supplementary Figure S6B). Since HO-1 also
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Figure 3. FD prevents H/R-induced dense cell formation and increased neutrophil counts in SS mice. (A) Hematocrit (Hct), hemoglobin (Hb),
and red cell distribution width (HDW) of AA and SS mice under a soy-diet (SD) or fish-oil diet (FD) under normoxia (white bars) and exposed to
hypoxia (black bars) (8% oxygen; 10 h) followed by reoxygenation (21% oxygen; 3 h) (H/R). (B) Red cell distribution histograms generated for
erythrocyte cell volume (RBC Volume) and cell hemoglobin concentration (RBC-HC). Red cell morphology is shown for each condition. (C)
Neutrophil counts in AA and SS mice treated as in (A) under normoxia (white bars) and exposed to hypoxia (black bars) (8% oxygen; 10 h) fol-
lowed by reoxygenation (21% oxygen; 3 h) (H/R). All statistical data are presented as means ± standard deviation (n=6; *P<0.005;
**P<0.002).  
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Table 2. Effects of ω−3 supplementation on lung and liver pathology of wild-type (AA) and sickle cell (SS) mice under normoxia and exposed to
hypoxia/reoxygenation stress 
AA-SD AA -FD SS-SD SS-FD
Normoxia H/R Normoxia H/R Normoxia H/R Normoxia H/R
Lung (n=3) (n=6) (n=3) (n=5) (n=3) (n=5) (n=3) (n=5)
Inflammatory cell infiltrates + (1/3) + (2/6) + (1/3) + (2/5) +(2/3) + (2/5) +(2/3) + (3/5)
++ (3/5)
Edema 0 0 0 0 0 0 0 0
Mucus 0 + (3/6) 0 + (1/5) 0 + (1/5) 0 0
Thrombi - - - - - + (4/5) - +(2/5)
Liver (n=3) (n=6) (n=3) (n=5) (n=3) (n=5) (n=3) (n=6)
Inflammatory cell infiltrates 0 + (3/6) +(1/3) + (1/5) + (1/3), ++(1/3); + (1/5) +(2/3) + (3/6)
+++ (1/3) ++ (4/5) ++(1/3) ++(1/6)
Thrombi - - - - - + (2/5) - -
Score 2-2-0 2-2-1-0-0-0 1-1-0 1-1-0-0-0 3-3-3 3-3-3-4-4 2-3-3 2-2-3-3-4-4-
SD: soy-diet; FD: fish-oil diet; H/R: hypoxia/reoxygenation.  Lungs: Thrombi: 0: no thrombi, + presence of thrombus per field at the magnification x250. Mucus: 0: no mucus, +: mucus
filling < 25 % of the area of the bronchus circumference; ++ mucus filling 25-50% of the area of the bronchus circumference;  +++: 50-100% of the area of the bronchus circumference
at magnification x400.  Inflammatory cell infiltrate: + 1-10 cells per field at magnification of x250; ++: 10-50 cells per field at magnification of x250; +++: > 50 cells per field at mag-
nification x250 Liver: + : 1-10 cells per field at magnification x 400; ++: 10-50 cells per field at magnification x 400; +++: >50 cells per field at magnification x 400; Liver score; 0: no
hepatocellular damage. 1: mild injury characterized by cytoplasmic vacuolization and focal nuclear pyknosis. 2: moderate injury with dilated sinusoids, cytosolic vacuolization, and
blurring of intercellular borders. 3: moderate to severe injury with coagulative necrosis, abundant sinusoidal dilatation, red blood extravasation into hepatic chords, hypereosinophil-
ia and migration of neutrophils. 4: severe necrosis with loss of hepatic architecture, disintegration of hepatic chords, hemorrhage and neutrophil infiltration.
Figure 4. FD reduces H/R-induced lung damage and prevents H/R-induced ET-1 up-regulation. (A-
D) Hematoxylin and eosin-stained sections of lung tissue at 400x magnification from SS mice
under a SD (A and C) or supplemented with FD (B and D) exposed to hypoxia (8% oxygen; 10 h) fol-
lowed by reoxygenation (21% oxygen; 3 h) (H/R). Lungs from SS mice given a FD have less inflam-
matory cellular infiltrate (B) and thrombi (D) than SS mice not fed FD (A and C).  (E) Upper panel.
BAL protein content from AA and SS mice treated as in (A-E). Lower panel. BAL leukocyte content
from AA and SS mice treated as in (A-E). White bars show data from mice under normoxia and
black bars show data from mice under H/R. (F) Immunoblot analysis with specific antibodies
against ET-1, VCAM-1, and HO-1 of lung from AA and SS mice treated as in (A-E). One representa-
tive gel from six with similar results is presented. Densitometric analysis of ET-1, VCAM-1 and HO-
1 immunoblots is shown in Online Supplementary Figure S4B. 
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plays a role as a heat shock protein (HSP32) in other ani-
mal models, such as the rat,41 we evaluated the hepatic
expression of HSP27, which is known to be important in
H/R liver injury.23,42 FD attenuated the H/R-induced HSP27
expression in SS mice compared to SS-SD animals (Figure
5E, Online Supplementary Figure S6B), supporting the anti-
inflammatory effects of ω-3 PUFA following H/R stress.
These findings align with data from other models of H/R
liver injury35,43 and confirm that VCAM-1 mediates adhe-
sion events in the hepatic microvasculature and con-
tributes to amplified inflammatory liver disease in SCD
mice. In livers from SS mice, FD prevented vascular activa-
tion and reduced inflammation, improving endothelial
dysfunction and reducing organ damage. 
Vascular protective effects of ω-3 polyunsaturated
fatty acids during acute vaso-occlusive crises
in sickle cell mice 
We isolated aortic tissue from AA and SS mice exposed
to H/R stress. As shown in Figure 6A, in SS mice, FD
reduced H/R-induced ET-1 and VCAM-1 expression com-
pared to SS-SD. This finding was associated with reduced
expression of acute inflammatory response-related pro-
teins such as HO-1, SOD-1 and peroxiredoxin-2 (Prx2)
(Figure 6A, see also Online Supplementary Figure S7 for den-
sitometric analysis). These effects were also evident in
AA-FD mice exposed to H/R compared to AA-SD mice
(Figure 6A). These results support the hypothesis that FD
attenuates endothelial dysfunction in SCD by reducing
vascular activation, vasoconstriction, inflammation and
oxidative stress. 
Discussion
The effects of ω-3 fatty acid supplementation have been
widely studied in cardiovascular diseases and in other dis-
orders characterized by acute or chronic vascular damage
and an amplified inflammatory response.44,45 In SCD, vas-
culopathy, inflammation and intravascular oxidative stress
are crucial in the pathogenesis of acute and chronic clinical
complications. Recent reports on the beneficial effects of
ω-3 fatty acid supplementation on the human hematologic
phenotype of SCD suggest a possible therapeutic effect of
ω-3 fatty acids in SCD.12-14 The present work provides evi-
dence for several relevant mechanisms underlying this
potential benefit. We propose that the beneficial role of ω-
3 PUFA on SCD vascular dysfunction might be exerted: (i)
directly through the reduction of ET-1 expression, which
is involved in adaptive inflammation, expression of adhe-
sion molecules such as VCAM-1, and neutrophil chemo-
taxis;46 and (ii) indirectly through reduced inflammation
and oxidative stress. Importantly, the ω-3 PUFA supple-
mentation in our study is comparable to that achieved in
recent human studies.47
In SS mice, ω-3 PUFA consistently modulate ET-1, a
potent vasoconstrictor, in agreement with recent meta-
analyses demonstrating a significant improvement in
flow-mediated dilation in subjects supplemented with
FD.45,48 This is of particular interest in the context of SCD,
in which ET-1 has been implicated in severe clinical com-
plications of SCD.28,49 The positive impact of FD on ET-1 is
not limited to the aorta but also involves the pulmonary
vascular bed, where we observed a decrease in the abnor-
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Figure 5. FD reduces H/R-induced liver damage and vascular activation. (A-D) Hematoxylin and eosin-stained sections of liver tissue at 400x mag-
nification from SS mice under a SD (A and C) or FD supplementation (B and D) exposed to H/R. Livers from mice given FD have less inflammatory
cellular infiltrate (B) and thrombi (D) than livers from SS mice fed a SD.  The infiltrate shown best in (B) is composed mostly of lymphocytes.
Scattered hemosiderin deposits and areas of necrosis are also present. (E) Immunoblot analysis with specific antibodies against ET-1, VCAM-1,
HO-1, and heat shock protein-27 (HSP27) of liver from AA and SS mice treated as in (A-D). One representative gel from six with similar results is
presented. Densitometric analysis of ET-1, VCAM-1, HO-1 and HSP27 immunoblots is shown in Online Supplementary Figure S5.
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mal pulmonary vascular leakage and a decrease in the
accumulation of protein and inflammatory cells in the
alveolar space (Figure 2A,B).  
To explore the critical balance between vascular tone
and endothelial activation in SCD, we used a H/R stress
model, which mimics the acute organ damage observed in
SCD VOC (Figures 4 and 5; Table 2).19,50 Compared to SD,
FD significantly reduced H/R-related ET-1 expression in
the aorta (Figure 6). This was accompanied by a significant
reduction in both ET-1 and ET-1BR expression in lungs
from SS-FD mice (Fig. 4F, Online Supplementary 5SA), sug-
gesting that the beneficial effects of FD treatment on H/R-
induced pulmonary vascular permeability might be related
to the combination of both ligand and target reduction in
the ET-1 system.33,51 No significant changes in ET-1 expres-
sion were observed between livers from H/R-exposed SS-
FD and SS-SD mice (Figure 5), most likely because of the
peculiar organization of liver vasculature or because of the
organ’s sensitivity in the context of H/R stress used in the
present study. 
We then evaluated the effects of FD on VCAM-1 expres-
sion, since elevated VCAM-1 has been associated with a
severe SCD phenotype and increased risk of early
death.49,52,53 In conditions of normoxia, FD significantly
reduced VCAM-1 expression in aortas and hearts of SS
mice compared to SS-SD mice (Figure 1B,C). This was
associated with improved left ventricular outflow tract
dimensions, suggesting a possible contribution of FD in
delaying the progression of SCD cardiovascular disease.54-
56 We demonstrated a synergistic effect of ω-3 PUFA on
both ET-1-mediated endothelial dysfunction and VCAM-
1-mediated endothelial activation on aortas following H/R
(Figure 6A). Notably, FD also significantly reduced
VCAM-1 expression in livers of SS mice exposed to H/R
stress compared to the expression in SS-SD mice (Figure
5). These data support a multimodal therapeutic action of
FD on both arterial and microvascular sites, preventing
vascular activation and possible amplification of local pro-
inflammatory events during acute VOC.
HO-1 is a key cytoprotector interfacing between vascu-
lar dysfunction and oxidative stress in SCD.23,30 Under nor-
moxia, ω-3 PUFA significantly reduced HO-1 expression in
the aorta, heart and liver of SS mice (Figure 1B and 2C).
Interestingly, FD did not affect lung HO-1 expression in SS
mice, even though a pulmonary anti-inflammatory effect
for FD supplementation was observed (i.e. reduced neu-
trophil counts in BAL fluid and reduced pulmonary cell
infiltrates) (Figures 2 and 4). This suggests that, under
steady state conditions, the anti-inflammatory effects of
FD on lungs of SCD mice may be more related to down-
regulation of ET-1. During acute VOC mimicked by H/R
stress, FD reduced HO-1 expression, indicating a stronger
role of ω-3 PUFA in acute events involving the lung than in
the steady state condition. This is in agreement with recent
studies on the protective role of ω-3-derived pro-resolving
mediators in models of acute lung injury.57,58 The pro-
resolving effects of FD supplementation during H/R stress
were also evident in aortas of SS-FD mice, in which we
observed a marked reduction in H/R-induced HO-1 expres-
sion and prevention of the H/R-induced expression of anti-
oxidant systems such as SOD-1 and Prx2 (Figure 6A). 
In livers from SCD mice exposed to H/R stress, FD was
associated with HO-1 mRNA down-regulation and a
marked decrease in the expression of HSP27, which is a
crucial liver cytoprotector against H/R stress.42 This finding
supports the anti-inflammatory activity of FD in reducing
liver injury during H/R stress in SCD mice. 
Finally, we observed a reduction in dense red cell for-
mation in SS-FD mice exposed to H/R compared to SS-SD
mice, which may contribute to the multimodal action of
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Figure 6. FD prevents H/R-induced ET-1 expression, vascular activation and modulates anti-oxidant systems. (A) Immunoblot analysis with spe-
cific antibodies against ET-1, VCAM-1, HO-1, SOD-1, and peroxiredoxin-2 (Prx-2) of isolated aortas from AA and SS under a SD or FD and
exposed to H/R. One representative gel from six with similar results is presented. Densitometric analysis of ET-1, VCAM-1 and HO-1
immunoblots is shown in Online Supplementary Figure S7. (B) Schematic diagram of effects of ω-3 fatty supplementation on acute vaso-occlu-
sive crises (VOC) in a mouse model of SCD. ω-3 fatty supplementation (i) beneficially affects sickle red cell membrane composition, with a
shift towards an anti-inflammatory substrate (ii) has potent anti-inflammatory action in target organs for SCD such as lung and liver; (iii)
improves vascular dysfunction through either a reduction of ET-1 (lung) or VCAM-1 (liver) or the synergizing decrease of both molecules in aorta. 
A B
ω-3 PUFA on SCD vasculopathy. Changes in membrane
lipid composition might affect red cell deformability, as
recently shown in a mouse model supplemented with ω-
3 PUFA (docosahexaenoic acid),59 as well as variations in
pro-inflammatory arachidonic acid incorporated into
sickle erythrocytes.60 These red cell changes may play a
role in reducing the systemic pro-inflammatory environ-
ment, which contributes to the pathogenesis of vascu-
lopathy in SCD.6
In summary, we propose that ω-3 PUFA may limit sickle
cell-related acute damage by: (i) shifting the sickle red cell
membrane towards an anti-inflammatory substrate; (ii)
exerting local anti-inflammatory effects in target organs
for SCD (lung, liver); (iii) improving vascular dysfunction
through the reduction of VCAM-1 or ET-1 or the synergis-
tic decrease of both molecules. This functional model sup-
ports the preliminary results of a clinical trial with ω-3
PUFA supplementation in SCD patients, which showed a
reduction in the rate and severity of painful crises.13 Taken
together, our data add significant new elements to the
mechanism of action of ω-3 PUFA in SCD, and generate a
rationale for future studies focused on the bioactive
metabolites of ω-3 PUFA.
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